Hologic (HOLX) 10-Q 27 Jul 22 2022 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Jun. 25, 2022	Jul. 21, 2022
Cover [Abstract]
Title of 12(b) Security	Common Stock, $0.01 par value
Document Transition Report	false
Document Quarterly Report	true
Entity Incorporation, State or Country Code	DE
Entity Address, Postal Zip Code	01752
Entity File Number	1-36214
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 25, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Registrant Name	HOLOGIC, INC
Entity Central Index Key	0000859737
Current Fiscal Year End Date	--09-28
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding		249,653,133
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
City Area Code	(508)
Local Phone Number	263-2900
Entity Tax Identification Number	04-2902449
Entity Address, Address Line One	250 Campus Drive,
Entity Address, City or Town	Marlborough,
Entity Address, State or Province	MA
Trading Symbol	HOLX
Security Exchange Name	NASDAQ

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Millions	3 Months Ended		9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021	Jun. 25, 2022	Jun. 26, 2021
Revenues:
Product	$ 837.1	$ 995.2	$ 3,408.7	$ 3,829.4
Service and other	165.6	173.1	500.9	486.3
Revenues	1,002.7	1,168.3	3,909.6	4,315.7
Costs of revenues:
Product	266.3	303.9	907	889.1
Amortization, Cost of Goods Sold	75.9	68.1	223.1	194.2
Impairment of acquired intangible assets	9.2	0	9.2	0
Service and other	101.5	94.7	287.6	264.7
Gross profit	549.8	701.6	2,482.7	2,967.7
Operating expenses:
Research and development	65.1	69	207.4	199.8
Selling and marketing	152.3	142.7	471	402.2
General and administrative	91.9	117.3	310.5	297.7
Amortization of acquired intangible assets	11.2	10.4	33.2	30.7
Contingent consideration - fair value adjustments	(35.4)	0	(39.5)	(10.1)
Restructuring and divestiture charges	0.8	3.6	0.8	6.6
Operating expenses	285.9	343	983.4	926.9
Income from operations	263.9	358.6	1,499.3	2,040.8
Interest income	2.4	0.4	3.6	1.1
Interest expense	(22.7)	(21.6)	(71)	(70.9)
Debt extinguishment loss	0	0	(0.7)	(21.6)
Other income, net	4.8	0.1	13.6	1.1
Income before income taxes	248.4	337.5	1,444.8	1,950.5
Provision for income taxes	20	69.4	261.5	409.6
Net income	228.4	268.1	1,183.3	1,540.9
Net loss attributable to noncontrolling interest	0	(0.3)	0	(1.8)
Net income attributable to Hologic	$ 228.4	$ 268.4	$ 1,183.3	$ 1,542.7
Net income per common share attributable to Hologic:
Basic (in usd per share)	$ 0.91	$ 1.05	$ 4.70	$ 5.98
Diluted (in usd per share)	$ 0.90	$ 1.04	$ 4.65	$ 5.93
Weighted average number of shares outstanding:
Basic (in shares)	250,756	256,230	251,943	257,769
Diluted (in shares)	253,093	258,581	254,273	260,371

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021	Jun. 25, 2022	Jun. 26, 2021
Statement of Comprehensive Income [Abstract]
Net income	$ 228.4	$ 268.1	$ 1,183.3	$ 1,540.9
Changes in foreign currency translation adjustment	(52)	(9.4)	(124.3)	(1)
Gain recognized in other comprehensive income, net	8.4	3	35.7	8
Loss reclassified from accumulated other comprehensive loss to the statements of income	0	0	0	0.5
Other comprehensive (loss) income	(43.6)	(6.4)	(88.6)	7.5
Comprehensive income	184.8	261.7	1,094.7	1,548.4
Comprehensive loss attributable to noncontrolling interest	0	0.3	0	1.8
Comprehensive Income	$ 184.8	$ 262	$ 1,094.7	$ 1,550.2

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Loss (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021	Jun. 25, 2022	Jun. 26, 2021
Statement of Comprehensive Income [Abstract]
Net unrealized loss	$ 2.5	$ 1	$ 11.6	$ 2.2

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 25, 2022	Sep. 25, 2021
Current assets:
Cash and cash equivalents	$ 2,375.3	$ 1,170.3
Accounts receivable, less reserves	702.9	942.7
Inventories	581.2	501.2
Prepaid Expense, Current	213.3	528.8
Prepaid Income Taxes-Current	36.3	25.7
Total current assets	3,909	3,168.7
Property, plant and equipment, net	490.1	564.7
Intangible assets, net	1,436.5	1,659.2
Goodwill	3,285.9	3,281.6
Other assets	235.9	245.7
Total assets	9,357.4	8,919.9
Current liabilities:
Current portion of long-term debt	7.5	313
Accounts payable	216.6	215.9
Accrued expenses	573.7	596.2
Deferred revenue	199.6	198
Finance lease obligations	3.5	3.7
Total current liabilities	1,000.9	1,326.8
Long-term debt, net of current portion	2,814.6	2,712.2
Finance lease obligations, net of current portion	18.9	22.8
Deferred Income Tax Liabilities, Net	208.3	250.5
Deferred revenue, net of current portion	10.9	20.3
Other long-term liabilities	305.9	368.7
Stockholders’ equity:
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued	0	0
Common stock, $0.01 par value – 750,000 shares authorized; 298,335 and 297,306 shares issued, respectively	3	3
Additional paid-in-capital	6,017.4	5,965.8
Retained earnings	1,481.6	298.3
Treasury stock, at cost – 48,851 and 43,653 shares, respectively	(2,356.4)	(1,989.4)
Accumulated other comprehensive loss	(147.7)	(59.1)
Total stockholders’ equity	4,997.9	4,218.6
Total liabilities and stockholders’ equity	$ 9,357.4	$ 8,919.9

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 25, 2022	Sep. 25, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 10,000	$ 10,000
Preferred stock, authorized (in shares)	1,623,000,000	1,623,000,000
Preferred stock, issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 10,000	$ 10,000
Common stock, authorized (in shares)	750,000,000,000	750,000,000,000
Common stock, issued (in shares)	298,335,000,000	297,306,000,000
Treasury stock (in shares)	48,851,000,000	43,653,000,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Millions	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Total	Treasury Stock
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount	$ 2.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	2,707.3
Balance (in shares) at Sep. 26, 2020		295,107				37,609
Beginning balance at Sep. 26, 2020		$ 2.9	$ 5,904.8	$ (1,573.2)	$ (49.7)	$ (1,579.6)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		490
Exercise of stock options			18.4
Change in par value	0.1
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)		936
Vesting of restricted stock units, net of shares withheld for employee taxes	(46.4)		(46.5)
Stock-based compensation expense			18.6
Net income	653.4
Other comprehensive income activity					19
Repurchase of common stock (in shares)						1,469
Repurchase of common stock	(101.3)					$ (101.3)
Balance (in shares) at Dec. 26, 2020		296,533				39,078
Ending balance at Dec. 26, 2020		$ 3	5,895.3	(918.8)	(30.7)	$ (1,680.9)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss attributable to noncontrolling interest	(1)
Net income	654.4
Balance (in shares) at Sep. 26, 2020		295,107				37,609
Beginning balance at Sep. 26, 2020		$ 2.9	5,904.8	(1,573.2)	(49.7)	$ (1,579.6)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,540.9
Balance (in shares) at Jun. 26, 2021		296,945				43,653
Ending balance at Jun. 26, 2021		$ 3	5,936.2	(30.5)	(42.2)	$ (1,989.4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss attributable to noncontrolling interest	(1.8)
Net income	1,542.7
Payments to Noncontrolling Interests	(8.5)
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount	1.1
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	3,269
Balance (in shares) at Dec. 26, 2020		296,533				39,078
Beginning balance at Dec. 26, 2020		$ 3	5,895.3	(918.8)	(30.7)	$ (1,680.9)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		146
Exercise of stock options			5.8
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)		17
Vesting of restricted stock units, net of shares withheld for employee taxes	(0.3)		(0.3)
Common stock issued under the employee stock purchase plan (in shares)		191
Common stock issued under the employee stock purchase plan			9.2
Stock-based compensation expense			17.1
Net income	619.4
Other comprehensive income activity					(5.1)
Repurchase of common stock (in shares)						1,604
Repurchase of common stock	(120.1)					$ (120.1)
Balance (in shares) at Mar. 27, 2021		296,887				40,682
Ending balance at Mar. 27, 2021		$ 3	5,927.1	(298.9)	(35.8)	$ (1,801)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss attributable to noncontrolling interest	(0.5)
Net income	619.9
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount	0.6
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	3,795
Exercise of stock options (in shares)		53
Exercise of stock options			2.1
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)		5
Vesting of restricted stock units, net of shares withheld for employee taxes	(0.2)		(0.2)
Stock-based compensation expense			15.4
Net income	268.1
Other comprehensive income activity					(6.4)
Repurchase of common stock (in shares)						2,971
Repurchase of common stock	(188.4)					$ (188.4)
Total payments to non-controlling interest	(8.5)
Purchase of non-controlling interest reclassified to APIC	(8.2)
Balance (in shares) at Jun. 26, 2021		296,945				43,653
Ending balance at Jun. 26, 2021		$ 3	5,936.2	(30.5)	(42.2)	$ (1,989.4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss attributable to noncontrolling interest	(0.3)
Net income	268.4
Payments to Noncontrolling Interests	(0.3)
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount	0
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	3,877.1
Exercise of stock options (in shares)		168
Exercise of stock options			6.6
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)		22
Vesting of restricted stock units, net of shares withheld for employee taxes	(0.6)		(0.6)
Common stock issued under the employee stock purchase plan (in shares)		171
Common stock issued under the employee stock purchase plan			9.7
Stock-based compensation expense			13.9
Net income	328.8
Other comprehensive income activity					(16.9)
Balance (in shares) at Sep. 25, 2021		297,306				43,653
Ending balance at Sep. 25, 2021	4,218.6	$ 3	5,965.8	298.3	(59.1)	$ (1,989.4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	328.8
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount	0
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	4,218.6
Exercise of stock options (in shares)		45
Exercise of stock options			1.9
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)		534
Vesting of restricted stock units, net of shares withheld for employee taxes	(22.4)		(22.4)
Stock-based compensation expense			18.7
Net income	499.2
Other comprehensive income activity					(29.9)
Repurchase of common stock (in shares)						2,335
Repurchase of common stock	(167)					$ (167)
Balance (in shares) at Dec. 25, 2021		297,885				45,988
Ending balance at Dec. 25, 2021		$ 3	5,964	797.5	(89)	$ (2,156.4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	499.2
Balance (in shares) at Sep. 25, 2021		297,306				43,653
Beginning balance at Sep. 25, 2021	4,218.6	$ 3	5,965.8	298.3	(59.1)	$ (1,989.4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,183.3
Balance (in shares) at Jun. 25, 2022		298,335				48,851
Ending balance at Jun. 25, 2022	4,997.9	$ 3	6,017.4	1,481.6	(147.7)	$ (2,356.4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss attributable to noncontrolling interest	0
Net income	1,183.3
Payments to Noncontrolling Interests	0
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	4,519.1
Balance (in shares) at Dec. 25, 2021		297,885				45,988
Beginning balance at Dec. 25, 2021		$ 3	5,964	797.5	(89)	$ (2,156.4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		140
Exercise of stock options			5.8
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)		14
Vesting of restricted stock units, net of shares withheld for employee taxes	(0.1)		(0.1)
Common stock issued under the employee stock purchase plan (in shares)		164
Common stock issued under the employee stock purchase plan			9.5
Stock-based compensation expense			17.8
Net income	455.7
Other comprehensive income activity					(15.1)
Repurchase of common stock (in shares)						2,863
Repurchase of common stock						$ (200)
Balance (in shares) at Mar. 26, 2022		298,203				48,851
Ending balance at Mar. 26, 2022		$ 3	5,997	1,253.2	(104.1)	$ (2,356.4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	455.7
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	4,792.7
Exercise of stock options (in shares)		128
Exercise of stock options			5.2
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)		4
Vesting of restricted stock units, net of shares withheld for employee taxes	(0.1)		(0.1)
Stock-based compensation expense			15.3
Net income	228.4
Other comprehensive income activity					(43.6)
Balance (in shares) at Jun. 25, 2022		298,335				48,851
Ending balance at Jun. 25, 2022	4,997.9	$ 3	$ 6,017.4	$ 1,481.6	$ (147.7)	$ (2,356.4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss attributable to noncontrolling interest	0
Net income	228.4
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 4,997.9

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021
OPERATING ACTIVITIES
Net income	$ 1,183.3	$ 1,540.9
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	67.2	64.2
Amortization of acquired intangibles	256.3	224.9
Stock-based compensation expense	51.8	51
Deferred income taxes	(60.2)	(44.3)
Intangible asset impairment charge	9.2	0
Debt extinguishment loss	0.7	21.6
Change in contingent consideration	(39.5)	(10.1)
Other adjustments and non-cash items	36.3	29.9
Changes in operating assets and liabilities, excluding the effect of acquisitions:
Accounts receivable	193.9	111.5
Inventories	(86.8)	(82.4)
Prepaid income taxes	(10.5)	(24.3)
Prepaid expenses and other assets	378.3	(22.3)
Accounts payable	2.5	9.4
Accrued expenses and other liabilities	(23)	(27.6)
Deferred revenue	(2.4)	22.6
Net cash provided by operating activities	1,957.1	1,865
INVESTING ACTIVITIES
Acquisition of businesses, net of cash acquired	(158.6)	(1,163.3)
Capital expenditures	(50.8)	(90.6)
Proceeds from the Department of Defense	75	19.4
Increase in equipment under customer usage agreements	(44.8)	(43.4)
Purchase of intellectual property	0	(6.5)
Other activity	5	(2.1)
Net cash used in investing activities	(174.2)	(1,286.5)
FINANCING ACTIVITIES
Proceeds from long-term debt, net of issuance costs	1,491.2	0
Repayment of long-term debt	(1,387.5)	(56.3)
Proceeds from Notes Payable	0	936.3
Repayments of Senior Debt	0	(970.8)
Proceeds from accounts receivable securitization agreement	0	320
Repayments of Accounts Receivable Securitization	(248.5)	0
Repayments under revolving credit line	0	(250)
Payment of deferred acquisition consideration	(12.2)	0
Payments to Noncontrolling Interests	0	(8.5)
Repayments of acquired long term debt	(63.7)	0
Repurchase of common stock	(367)	(409.7)
Proceeds from issuance of common stock pursuant to employee stock plans	26.9	39.6
Payment of minimum tax withholdings on net share settlements of equity awards	(22.6)	(46.9)
Payments under finance lease obligations	(2.8)	(1.5)
Net cash used in financing activities	(586.2)	(447.8)
Effect of exchange rate changes on cash and cash equivalents	8.3	(4.1)
Net increase in cash and cash equivalents	1,205	126.6
Cash and cash equivalents, beginning of period	1,170.3	701
Cash and cash equivalents, end of period	$ 2,375.3	$ 827.6

Basis of Presentation

Basis of Presentation	9 Months Ended
	Jun. 25, 2022
Basis of Presentation [Abstract]
Basis of Presentation	Basis of Presentation The unaudited consolidated financial statements of Hologic, Inc. (“Hologic” or the “Company”) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (the “SEC”) for quarterly reports on Form 10-Q and do not include all of the information and disclosures required by U.S. generally accepted accounting principles (“GAAP”) for annual financial statements. These unaudited financial statements should be read in conjunction with the consolidated financial statements and related notes for the fiscal year ended September 25, 2021 included in the Company’s Form 10-K filed with the SEC on November 16, 2021. In the opinion of management, the unaudited financial statements and notes contain all adjustments (consisting of normal recurring accruals and all other necessary adjustments) considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented. The unaudited consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The preparation of financial statements in conformity with GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate. Operating results for the three and nine months ended June 25, 2022 are not necessarily indicative of the results to be expected for any other interim period or the entire fiscal year ending September 24, 2022. Subsequent Events Consideration

Revenue

Revenue	9 Months Ended
	Jun. 25, 2022
Revenue from Contract with Customer [Abstract]
Revenue	Revenue The Company accounts for revenue pursuant to ASC 606, Revenue from Contracts with Customer (ASC 606) and generates revenue from the sale of its products, primarily medical imaging systems and related components and software, diagnostic tests and assays and surgical disposable products, and related services, which are primarily support and maintenance services on its medical imaging systems, and to a lesser extent installation, training and repairs. In addition, the Company generates service revenue from performing laboratory testing services acquired in its Biotheranostics, Inc. acquisition, which are included in its Molecular Diagnostics business. The Company's products are sold primarily through a direct sales force, and within international markets, there is more reliance on distributors and resellers. Revenue is recorded net of sales tax. The following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis: Three Months Ended June 25, 2022 Three Months Ended June 26, 2021 Business ( in millions ) United States International Total United States International Total Diagnostics: Cytology & Perinatal $ 74.3 $ 41.6 $ 115.9 $ 73.9 $ 42.0 $ 115.9 Molecular Diagnostics 304.2 131.1 435.3 270.1 266.3 536.4 Blood Screening 8.9 — 8.9 13.2 — 13.2 Total $ 387.4 $ 172.7 $ 560.1 $ 357.2 $ 308.3 $ 665.5 Breast Health: Breast Imaging $ 165.5 $ 46.7 $ 212.2 $ 218.4 $ 61.9 $ 280.3 Interventional Breast Solutions 56.8 13.8 70.6 54.8 13.9 68.7 Total $ 222.3 $ 60.5 $ 282.8 $ 273.2 $ 75.8 $ 349.0 GYN Surgical $ 112.2 $ 25.9 $ 138.1 $ 103.9 $ 24.0 $ 127.9 Skeletal Health $ 12.7 $ 9.0 $ 21.7 $ 15.6 $ 10.3 $ 25.9 $ 734.6 $ 268.1 $ 1,002.7 $ 749.9 $ 418.4 $ 1,168.3 Nine Months Ended June 25, 2022 Nine Months Ended June 26, 2021 Business (in millions) United States International Total United States International Total Diagnostics: Cytology & Perinatal $ 227.4 $ 134.6 $ 362.0 $ 230.8 $ 127.1 $ 357.9 Molecular Diagnostics 1,395.9 715.2 2,111.1 1,561.7 905.3 2,467.0 Blood Screening 24.5 — 24.5 33.3 — 33.3 Total $ 1,647.8 $ 849.8 $ 2,497.6 $ 1,825.8 $ 1,032.4 $ 2,858.2 Breast Health: Breast Imaging $ 561.8 $ 177.7 $ 739.5 $ 619.5 $ 198.3 $ 817.8 Interventional Breast Solutions 171.1 42.1 213.2 164.9 35.3 200.2 Total $ 732.9 $ 219.8 $ 952.7 $ 784.4 $ 233.6 $ 1,018.0 GYN Surgical $ 315.4 $ 74.2 $ 389.6 $ 296.8 $ 69.4 $ 366.2 Skeletal Health $ 43.3 $ 26.4 $ 69.7 $ 44.7 $ 28.6 $ 73.3 $ 2,739.4 $ 1,170.2 $ 3,909.6 $ 2,951.7 $ 1,364.0 $ 4,315.7 Three Months Ended Nine Months Ended Geographic Regions ( in millions ) June 25, 2022 June 26, 2021 June 25, 2022 June 26, 2021 United States $ 734.6 $ 749.9 $ 2,739.4 $ 2,951.7 Europe 164.5 289.0 750.8 963.9 Asia-Pacific 71.7 89.6 301.1 268.1 Rest of World 31.9 39.8 118.3 132.0 $ 1,002.7 $ 1,168.3 $ 3,909.6 $ 4,315.7 The following table provides revenue recognized by source: Three Months Ended Nine Months Ended Revenue by type (in millions) June 25, 2022 June 26, 2021 June 25, 2022 June 26, 2021 Disposables $ 713.0 $ 797.7 $ 2,930.5 $ 3,239.2 Capital equipment, components and software 124.1 197.5 478.2 590.2 Service 160.8 158.4 486.2 437.2 Other 4.8 14.7 14.7 49.1 $ 1,002.7 $ 1,168.3 $ 3,909.6 $ 4,315.7 The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount the Company expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods and services expected to be transferred. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. Transfer of control for the Company's products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the point in time when the customer obtains the use of and substantially all of the remaining benefits of the product. As such, the Company's performance obligation related to product sales is satisfied at a point in time. Revenue from support and maintenance contracts, extended warranty, and professional services for installation, training and repairs is recognized over time based on the period contracted or as the services are performed as these methods represent a faithful depiction of the transfer of goods and services. The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction and is most often equal to the transaction price in the contract. Payment terms are typically 30 days in the U.S. but may be longer in international markets. The Company treats shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and records these costs within costs of product revenue when the corresponding revenue is recognized. The Company also places instruments (or equipment) at customer sites but retains title to the instrument. The customer has the right to use the instrument for a period of time, and the Company recovers the cost of providing the instrument through the sales of disposables, namely tests and assays in Diagnostics and handpieces in GYN Surgical. These types of agreements include an embedded lease, which is generally an operating lease, for the right to use an instrument and no instrument revenue is recognized at the time of instrument delivery. The Company recognizes a portion of the revenue allocated to the embedded lease concurrent with the sale of disposables over the term of the agreement. Some of the Company's contracts have multiple performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price to each performance obligation using its best estimate of the standalone selling price of each distinct good or service in the contract. The Company determines its best estimate of standalone selling price using average selling prices over 3- to 12-month periods of data depending on the products or nature of the services coupled with current market considerations. If the product or service does not have a history of sales or if sales volume is not sufficient, the Company relies on prices set by its pricing committees or applicable marketing department adjusted for expected discounts. Variable Consideration The Company exercises judgment in estimating variable consideration, which includes volume discounts, sales rebates, product returns and other adjustments. These amounts are recorded as a reduction to revenue and classified as a current liability. The Company bases its estimates for volume discounts, sales rebates and product returns on historical information to the extent it is reasonable to be used as a predictive tool of expected future rebates. To the extent the transaction price includes variable consideration, the Company applies judgment in constraining the estimated variable consideration due to factors that may cause reversal of revenue recognized. The Company evaluates constraints based on its historical and projected experience with similar customer contracts. The Company's contracts for the sale of capital equipment and related components, and assays and tests typically do not provide the right to return product, however, its contracts for the sale of its surgical handpieces provide for a right of return for a limited period of time. In general, estimates of variable consideration and constraints are not material to the Company's financial statements. Remaining Performance Obligations As of June 25, 2022, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was approximately $844.4 million. These remaining performance obligations primarily relate to support and maintenance obligations and extended warranty in the Company's Breast Health and Skeletal Health reportable segments. The Company expects to recognize approximately 12% of this amount as revenue in fiscal 2022, 39% in fiscal 2023, 26% in fiscal 2024, 15% in fiscal 2025, and 8% thereafter. The Company has applied the practical expedient to not include remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above. Contract Assets and Liabilities The Company discloses accounts receivable separately in the Consolidated Balance Sheets at their net realizable value. Contract assets primarily relate to the Company's conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were immaterial.

Leases

Leases	9 Months Ended
	Jun. 25, 2022
Leases [Abstract]
Leases	LeasesLessor Activity - Leases where Hologic is the LessorCertain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating lease and performance obligations for disposables, assays, tests and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. Sales-type leases are immaterial. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented less than 5% of the Company's consolidated revenue for all periods presented.
Leases	LeasesLessor Activity - Leases where Hologic is the LessorCertain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating lease and performance obligations for disposables, assays, tests and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. Sales-type leases are immaterial. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented less than 5% of the Company's consolidated revenue for all periods presented.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Jun. 25, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]	Fair Value Measurements Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis The Company has investments in derivative instruments comprised of an interest rate swap and forward foreign currency contracts, which are valued using analyses obtained from independent third party valuation specialists based on market observable inputs, representing Level 2 measurements. The fair values of these derivative contracts represent the estimated amounts the Company would receive or pay to terminate the contracts. Refer to Note 9 for further discussion and information on derivative instruments. Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at June 25, 2022: Fair Value at Reporting Date Using Balance as of June 25, 2022 Quoted Prices in Significant Significant Assets: Interest rate swap $ 28.6 $ — $ 28.6 $ — Forward foreign currency contracts 10.3 — 10.3 — Total $ 38.9 $ — $ 38.9 $ — Liabilities: Contingent consideration $ 23.4 $ — $ — $ 23.4 Total $ 23.4 $ — $ — $ 23.4 Liabilities Measured and Recorded at Fair Value on a Recurring Basis Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of contingent consideration liabilities, during the three and nine month periods ended June 25, 2022 and June 26, 2021 were as follows: Three Month Ended Nine Months Ended June 25, 2022 June 26, 2021 June 25, 2022 June 26, 2021 Balance at beginning of period $ 58.8 $ 71.7 $ 75.1 $ 81.8 Contingent consideration recorded at acquisition — — — — Fair value adjustments (35.4) — (39.5) (10.1) Payments — — (12.2) — Balance at end of period $ 23.4 $ 71.7 $ 23.4 $ 71.7 Assets Measured and Recorded at Fair Value on a Nonrecurring Basis The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets are comprised of equity investments and long-lived assets, including property, plant and equipment, intangible assets, goodwill and right of use assets. During the third quarter of fiscal 2022, the Company recorded a $9.2 million impairment charge to write-off two developed technology assets acquired in the Faxitron acquisition. During the first quarter of fiscal 2022, the Company recorded a $4.3 million charge to write-off an equity method investment. There were no other remeasurements in the three and nine months ended June 25, 2022 and June 26, 2021. Disclosure of Fair Value of Financial Instruments The Company’s financial instruments mainly consist of cash and cash equivalents, accounts receivable, equity investments, an interest rate swap, forward foreign currency contracts, insurance contracts, accounts payable and debt obligations. The carrying amounts of the Company’s cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The Company’s interest rate swap and forward foreign currency contracts are recorded at fair value. The carrying amount of the insurance contracts are recorded at the cash surrender value, as required by GAAP, which approximates fair value. The Company believes the carrying amounts of its equity investments approximate fair value.

Business Combinations

Business Combinations	9 Months Ended
	Jun. 25, 2022
Business Combinations [Abstract]
Business Combinations	Business Combinations Fiscal 2022 Acquisitions Bolder Surgical On November 29, 2021, the Company completed the acquisition of Bolder Surgical Holdings, Inc. ("Bolder"), for a purchase price of $160.1 million. Bolder, located in Louisville, Colorado, is a developer and manufacturer of energy vessel sealing surgical devices used in both laparoscopic and open procedures. Bolder's results of operations are reported in the Company's GYN Surgical reportable segment from the date of acquisition. The total purchase price was allocated to Bolder's preliminary tangible and identifiable intangible assets and liabilities based on the estimated fair values as of November 29, 2021, as set forth below. Cash $ 1.9 Accounts receivable 1.3 Inventory 3.3 Other assets 3.0 Accounts payable and accrued expenses (3.2) Identifiable intangible assets: Developed technology 73.6 Customer relationship 21.7 Trade names 1.4 Deferred income taxes, net (13.8) Goodwill 70.9 Purchase Price $ 160.1 In performing the preliminary purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of Bolder's business. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the acquired assets and liabilities, including, but not limited to, the estimate of fair value of identifiable intangible assets and deferred income taxes. As part of the preliminary purchase price allocation, the Company determined the identifiable intangible assets are developed technology, customer relationships and trade names. The preliminary fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using a 16.0% rate. The cash flows were based on estimates used to price the transaction, and the discount rate applied was benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The developed technology assets are comprised of know-how, patents and technologies embedded in Bolder's products and relate to currently marketed products. The developed technology assets comprise the primary product families under the JustRight and CoolSeal technology platforms. The preliminary estimate of the weighted average life for the developed technology, customer relationship, and trade name assets is 10 years. The preliminary calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Factors contributing to the recognition of the preliminary amount of goodwill were primarily based on anticipated strategic and synergistic benefits that are expected to be realized from the Bolder acquisition. These benefits include expanding the Company's surgical portfolio and utilizing GYN Surgical's sales and regulatory expertise to drive adoption and revenue growth. None of the goodwill is expected to be deductible for income tax purposes. Fiscal 2021 Acquisitions Mobidiag On June 17, 2021, the Company completed the acquisition of Mobidiag Oy ("Mobidiag"), for a purchase price of $729.6 million. Mobidiag, located in Finland, manufactures molecular diagnostic solutions for gastrointestinal infections, antimicrobial resistance management and other infections. Mobidiag's results of operations are reported in the Company's Diagnostics reportable segment from the date of acquisition. The total purchase price was allocated to Mobidiag's tangible and identifiable intangible assets and liabilities based on the estimated fair values as of June 17, 2021, as set forth below. Cash $ 7.0 Accounts receivable 4.2 Inventory 12.1 Other assets 29.6 Accounts payable and accrued expenses (16.5) Other liabilities (12.2) Identifiable intangible assets: Developed technology 285.0 In-process research and development 74.0 Customer relationships 20.9 Trade names 20.0 Long-term debt (66.1) Deferred income taxes, net (56.1) Goodwill 427.7 Purchase Price $ 729.6 In performing the purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of Mobidiag's business. As part of the purchase price allocation, the Company determined the identifiable intangible assets are development technology, in-process research and development ("IPR&D"), customer relationships and trade names. The fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using rates ranging from 15.0% to 19.0%. The cash flows were based on estimates used to price the transaction, and the discount rates applied were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The developed technology assets are comprised of know-how, patents and technologies embedded in Mobidiag's products and relate to currently marketed products. The developed technology assets comprise the primary product families under the Novodiag and Amplidiag technology platforms. The IPR&D project relates to an in-process project that had not reached technological feasibility as of the acquisition date and has no future alternative use. The primary basis for determining technological feasibility of the project is obtaining regulatory approval to market the underlying product. The asset recorded relates to one project, and the Company expects to complete the project in approximately three years. Given the uncertainties inherent with product development and introduction, there can be no assurance that the Company's product development efforts will be successful, completed on a timely basis or within budget, if at all. The IPR&D asset was valued using the income approach. The estimate of the weighted average life for the developed technology assets was 11.7 years, for customer relationships was 9.1 years, and for tradenames was 11.6 years. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Factors contributing to the recognition of the amount of goodwill were primarily based on anticipated strategic and synergistic benefits that are expected to be realized from the Mobidiag acquisition. These benefits include expanding the Company's molecular diagnostics portfolio into the near-patient testing market and utilizing Diagnostic's commercial sales, manufacturing and regulatory expertise to drive adoption and revenue growth. None of the goodwill is expected to be deductible for income tax purposes. Biotheranostics On February 22, 2021, the Company completed the acquisition of Biotheranostics, Inc. ("Biotheranostics"), for a purchase price of $231.3 million. Biotheranostics, located in San Diego, California, manufactures molecular diagnostic tests that support physicians in the treatment of breast cancer and all metastatic cancers and performs the lab testing procedures at its Clinical Laboratory Improvement Amendments ("CLIA") certified laboratory. Biotheranostics' results of operations are reported in the Company's Diagnostics reportable segment from the date of acquisition and its revenues are reported within Service and other revenue in the Company's Consolidated Statements of Income and within service revenue in the disclosure of disaggregated revenue in Note 2. The total purchase price was allocated to Biotheranostics' tangible and identifiable intangible assets and liabilities based on the estimated fair values as of February 22, 2021, as set forth below. Cash $ 9.6 Accounts receivable 6.6 Other assets 6.5 Accounts payable and accrued expenses (8.2) Other liabilities (8.1) Identifiable intangible assets: Developed technology 160.3 Trade names 2.1 Deferred income taxes, net (18.4) Goodwill 80.9 Purchase Price $ 231.3 In performing the purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of Biotheranostics' business. As part of the purchase price allocation, the Company determined the identifiable intangible assets are developed technology and trade names. The fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using a 18.0% rate. The cash flows were based on estimates used to price the transaction, and the discount rate applied was benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The weighted average life of developed technology and trade names was 10 years. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Factors contributing to the recognition of the amount of goodwill were primarily based on anticipated synergistic benefits of adding Biotheranostics' CLIA lab to the Company's portfolio of offerings and utilizing Diagnostic's marketing and regulatory expertise to drive adoption and revenue growth. None of the goodwill is expected to be deductible for income tax purposes. Diagenode On March 1, 2021, the Company completed the acquisition of Diagenode SA ("Diagenode") for a purchase price of $155.1 million. Diagenode, located in Belgium, is a developer and manufacturer of molecular diagnostic assays based on PCR (polymerase chain reaction) technology to detect infectious diseases of bacterial, viral and parasite origin. Diagenode's results of operations are reported in the Company's Diagnostics reportable segment from the date of acquisition. The total purchase price was allocated to Diagenode's tangible and identifiable intangible assets and liabilities based on the estimated fair values as of March 1, 2021, as set forth below. Cash $ 5.6 Accounts receivable 9.3 Inventory 9.0 Other assets 13.9 Accounts payable and accrued expenses (16.7) Other liabilities (9.2) Identifiable intangible assets: Developed technology 69.8 Customer relationships 9.2 Deferred income taxes, net (19.3) Goodwill 83.5 Purchase Price $ 155.1 In performing the purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of Diagenode's business. As part of the purchase price allocation, the Company determined the identifiable intangible assets are developed technology and customer relationships. The fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using a 14.5% rate for developed technology and a 13.5% rate for customer relationships. The cash flows were based on estimates used to price the transaction, and the discount rates applied were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The weighted average life of developed technology and customer relationships was 10 years. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Factors contributing to the recognition of the amount of goodwill were based on anticipated synergistic benefits of Diagenode's products broadening the Diagnostics portfolio of molecular diagnostics products primarily in the transplant and acute care gastrointestinal and respiratory space as customers seek a broader menu of tests, utilizing Diagnostic's sales force to drive menu expansion and revenue growth and gaining additional PCR assay development expertise. None of the goodwill is expected to be deductible for income tax purposes. Somatex Medical Technologies On December 30, 2020, the Company completed the acquisition of Somatex Medical Technologies GmbH ("Somatex") for a purchase price of $62.9 million. Somatex, located in Germany, is a manufacturer of biopsy site markers, including the Tumark product line of tissue markers, which were distributed by the Company in the U.S. prior to the acquisition. The allocation of the purchase price was based on the Company's valuation, and it allocated $38.0 million to the value of developed technology with a weighted average life of 8 years, $1.2 million to customer relationships, $0.9 million to trade names and $32.4 million to goodwill. The remaining $9.6 million of the purchase price was allocated to the net acquired tangible assets and liabilities. Somatex's results of operations are reported in the Company's Breast Health reportable segment from the date of acquisition. None of the goodwill is expected to be deductible for income tax purposes. NXC Imaging On September 28, 2020, the Company completed the acquisition of assets from NXC Imaging, for a purchase price of $5.6 million. NXC Imaging was a long-standing distributor of the Company's Breast and Skeletal products in the U.S. The majority of the purchase price was allocated to a customer relationships intangible asset with a useful life of 5 years. Contingent Consideration The Company has a contingent consideration liability related to its acquisition of Acessa Health, Inc. ("Acessa"), which occurred in August 2020. Acessa was the developer of the ProVu laparoscopic radiofrequency ablation system. The Company estimated the fair value of this liability to be $81.8 million at the date of acquisition. The contingent payments are based on a multiple of annual incremental revenue growth over a three-year period ending annually in December of each of 2021, 2022, and 2023. There is no maximum earnout. Pursuant to ASC 805, Business Combinations (ASC 805), the Company recorded its estimate of the fair value of the contingent consideration liability utilizing the Monte Carlo simulation based on future revenue projections of Acessa, revenue growth rates of comparable companies, implied volatility and applying a risk adjusted discount rate. Each quarter the Company is required to remeasure the fair value of the liability as assumptions change and such adjustments are recorded in operating expenses. This fair value measurement was based on significant inputs not observable in the market and thus represented a Level 3 measurement as defined in ASC 820, Fair Value Measurements

Trade Receivables and Allowance

Trade Receivables and Allowance for Credit Losses	9 Months Ended
	Jun. 25, 2022
Receivables [Abstract]
Trade Receivables and Allowance for Credit Losses	Trade Receivables and Allowance for Credit Losses Effective September 27, 2020, the Company adopted ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) , which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The expected credit losses are developed using an estimated loss rate method that considers historical collection experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The estimated loss rates are applied to trade receivables with similar risk characteristics such as the length of time the balance has been outstanding and the location of the customer. In certain instances, the Company may identify individual trade receivable assets that do not share risk characteristics with other trade receivables, in which case the Company records its expected credit losses on an individual asset basis. For example, potential adverse changes to customer liquidity from new macroeconomic events, such as the COVID-19 pandemic, must be taken into consideration. To date, the Company has not experienced significant customer payment defaults, or identified other significant collectability concerns as a result of the COVID-19 pandemic. In connection with assessing credit losses for individual trade receivable assets, the Company considers significant factors relevant to collectability including those specific to the customer such as bankruptcy, length of time an account is outstanding, and the liquidity and financial position of the customer. If a trade receivable asset is evaluated on an individual basis, the Company excludes those assets from the portfolios of trade receivables evaluated on a collective basis. The following is a rollforward of the allowance for credit losses as of June 25, 2022 compared to June 26, 2021: Balance at Credit Loss Write- Balance at Nine Months Ended June 25, 2022 $ 40.5 $ 4.4 $ (3.9) $ 41.0 June 26, 2021 $ 31.6 $ 11.6 $ (3.4) $ 39.8

Restructuring

Restructuring	9 Months Ended
	Jun. 25, 2022
Restructuring Costs [Abstract]
Restructuring and Related Activities Disclosure	(6) Restructuring During the first quarter of fiscal 2022, the Company finalized its decision to close its Danbury, Connecticut facility where it manufactures its Breast Health capital equipment products. The manufacturing of the Breast Health capital equipment products and all other support services will be moved to the Company's Newark, Delaware facility. In addition, research and development, sales and services support and administrative functions will be moved to the Newark, Delaware and Marlborough, Massachusetts facilities. The transition is expected to be completed by the third quarter of fiscal 2025. The majority of employees located in Danbury were given the option to relocate to the new locations. As a result of this plan, the Company expects a number of employees to not relocate resulting in their termination. The employees were notified of the closure during the first quarter of fiscal 2022, but were not communicated about their termination and related severance and benefits until the third quarter of fiscal 2022. The Company is recording severance benefits pursuant to pursuant to ASC 420, Exit or Disposal Cost Obligations (ASC 420) and the benefits will be expensed ratably over the required service period. As a result, the Company recorded $0.8 million of severance and benefits charges in the third quarter of fiscal 2022. The Company estimates that total severance and benefits charges, including retention, will be approximately $7.0 million.

Borrowings and Credit Arrangeme

Borrowings and Credit Arrangements	9 Months Ended
	Jun. 25, 2022
Debt Disclosure [Abstract]
Borrowings and Credit Arrangements	Borrowings and Credit Arrangements The Company’s borrowings consisted of the following: June 25, September 25, Current debt obligations, net of debt discount and deferred issuance costs: Term Loan $ 7.5 $ — Securitization Program — 248.5 Other — 64.5 Total current debt obligations $ 7.5 $ 313.0 Long-term debt obligations, net of debt discount and issuance costs: Term Loan 1,482.6 1,382.3 2028 Senior Notes 395.9 395.4 2029 Senior Notes 936.1 934.5 Total long-term debt obligations $ 2,814.6 $ 2,712.2 Total debt obligations $ 2,822.1 $ 3,025.2 2021 Credit Agreement On September 27, 2021, the Company and certain of its subsidiaries refinanced its term loan and revolving credit facility under its then credit agreement (the "2018 Credit Agreement") by entering into Refinancing Amendment No. 2 dated as of September 27, 2021, to the Amended and Restated Credit and Guaranty Agreement as of October 3, 2017, as amended (the "2021 Credit Agreement") with Bank of America, N.A. in its capacity as Administrative Agent, Swing Line Lender and L/C Issuer, and certain other lenders. Substantially all of the proceeds under the 2021 Credit Agreement of $1.5 billion were used to repay the amounts outstanding under the 2018 Credit Agreement. Borrowings under the 2021 Credit Agreement are secured by first-priority liens on, and a first-priority security interest in, substantially all of the Company's and its Subsidiary Guarantors' U.S. assets. These liens are subject to release during the term of the facilities if the Company is able to achieve certain corporate or corporate family ratings and other conditions are met. The credit facilities under the 2021 Credit Agreement (the "2021 Credit Facilities") consist of: • A $1.5 billion secured term loan ("2021 Term Loan") with a maturity date of September 25, 2026; and • A secured revolving credit facility ("2021 Revolver") under which the Company may borrow up to $2.0 billion, subject to certain sublimits, with a maturity date of September 25, 2026. Borrowings under the 2021 Credit Agreement, other than Swing Line Loans, bear interest, at the Company's option, at the Base Rate, at the Eurocurrency Rate, at the Alternative Currency Daily Rate, or at the LIBOR Daily Floating Rate, in each case plus the Applicable Rate (as such terms are defined in the 2021 Credit Agreement). The Applicable Rate in regards to the Base Rate, the Eurocurrency Rate, the Alternative Currency Daily Rate, the Alternative Currency Term Rate, and the LIBOR Daily Floating Rate is subject to change depending on the Total Net Leverage Ratio (as defined in the 2021 Credit Agreement). As of June 25, 2022, the interest rate under the 2021 Term Loan was 2.63% per annum. The Company is also required to pay a quarterly commitment fee calculated on daily basis equal to the Applicable Rate as of such day multiplied by the undrawn committed amount available under the 2021 Revolver (taking into account any outstanding amounts under the LC Sublimit). As of June 25, 2022, this commitment fee was 0.15% per annum. Upon the earliest to occur of June 30, 2023 and certain specified events, relating to the planned phase out of LIBOR by the UK Financial Conduct Authority, the interest rate applicable to the loans under the 2021 Credit Agreement denominated in U.S. Dollars will convert to a variant of the secured overnight financing rate (“SOFR”), as established from time to time by the Federal Reserve Bank of New York, plus a corresponding spread. The Company is required to make scheduled principal payments under the 2021 Term Loan in increasing amounts ranging from $3.75 million per three-month period commencing with the three-month period ending on December 29, 2022 to $18.75 million per three-month period commencing with the three month period ending on December 26, 2025. The remaining balance of $1.335 billion (or such lesser aggregate principal amount of Term Loans then outstanding) on the 2021 Term Loan and any amounts outstanding under the 2021 Revolver are due at maturity. In addition, subject to the terms and conditions set forth in the 2021 Credit Agreement, the Company is required to make certain mandatory prepayments from the net proceeds of specified types of asset sales (subject to certain reinvestment rights), debt issuances (excluding permitted debt) and insurance recoveries (subject to certain reinvestment rights). Certain of the mandatory prepayments are subject to reduction or elimination if certain financial covenants are met. These mandatory prepayments are required to be applied by the Company, first to the 2021 Term Loan, second to any outstanding amount under any Swing Line Loans, third to the 2021 Revolver, fourth to prepay any outstanding reimbursement obligations with respect to letters of credit and fifth to cash collateralize such letters of credit. Subject to certain limitations, the Company may voluntarily prepay any of the 2021 Credit Facilities without premium or penalty. As of June 25, 2022, the outstanding principal balance of the 2021 Term Loan was $1.5 billion, and there were no amounts outstanding under the 2021 Revolver. The 2021 Credit Agreement contains affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants restricting the ability of the Company, subject to negotiated exceptions, to incur additional indebtedness and grant additional liens on its assets, engage in mergers or acquisitions or dispose of assets, enter into sale-leaseback transactions, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments, and change the nature of their businesses. In addition, the 2021 Credit Agreement requires the Borrowers to maintain certain financial ratios. The 2021 Credit Agreement also contains customary representations and warranties and events of default, including payment defaults, breach of representations and warranties, covenant defaults, cross defaults and an event of default upon a change of control of the Company. The Company evaluated the 2021 Credit Agreement for derivatives pursuant to ASC 815, Derivatives and Hedging , and identified embedded derivatives that required bifurcation as the features are not clearly and closely related to the host instrument. The embedded derivatives were a default provision, which could require additional interest payments, and a provision requiring contingent payments to compensate the lenders for changes in tax deductions. The Company determined that the fair value of these embedded derivatives was immaterial as of June 25, 2022. Pursuant to ASC 470, Debt (ASC 470), the accounting for the refinancing was evaluated on a creditor-by-creditor basis to determine whether each transaction should be accounted for as a modification or extinguishment. Certain creditors under the 2018 Credit Agreement did not participate in this refinancing transaction and ceased being creditors of the Company. As a result, the Company recorded a debt extinguishment loss of $0.7 million in the first quarter of fiscal 2022 to write-off the pro-rata amount of unamortized debt discount and deferred issuance costs related to these creditors. For the remainder of the creditors, this transaction was accounted for as a modification. Pursuant to ASC 470, third-party costs of $7.0 million were recorded as a reduction to debt representing deferred issuance costs and fees paid directly to the lenders. Interest expense, weighted average interest rates, and the interest rate at the end of period under the 2021 and 2018 Credit Agreements were as follows: Three Months Ended Nine Months Ended June 25, 2022 June 26, 2021 June 25, 2022 June 26, 2021 Interest expense $ 7.8 $ 5.1 $ 18.8 $ 17.0 Weighted average interest rate 1.67 % 1.10 % 1.30 % 1.15 % Interest rate at end of period 2.63 % 1.09 % 2.63 % 1.09 % The 2021 Credit Agreement contains two financial covenants; a total leverage ratio and an interest coverage ratio, both of which are measured as of the last day of each fiscal quarter. These terms, and calculations thereof, are defined in further detail in the 2021 Credit Agreement. As of June 25, 2022, the Company was in compliance with these covenants. Senior Notes On September 28, 2020, the Company completed a private placement of $950 million aggregate principal amount of its Senior Notes due 2029 at an offering price of 100% of the aggregate principal amount of the 2029 Senior Notes. The Company used the net proceeds of the 2029 Senior Notes offering and cash on hand to redeem in full its 4.375% Senior Notes due 2025 (the "2025 Senior Notes") in the aggregate principal amount of $950.0 million on October 15, 2020 at an aggregate redemption price of $970.8 million, which included a premium payment $20.8 million. 2025 Senior Notes Immediately prior to redemption in full of the 2025 Senior Notes on October 15, 2020, the total aggregate principal balance of 2025 Senior Notes was $950.0 million. Since the Company used the proceeds from the 2029 Senior Notes offering to redeem the 2025 Senior Notes, the Company evaluated the accounting for this transaction under ASC 470 to determine modification versus extinguishment accounting on a creditor-by-creditor basis. Certain 2025 Senior Note holders either did not participate in this refinancing transaction or reduced their holdings, and these transactions were accounted for as extinguishments. As a result, the Company recorded a debt extinguishment loss in the first quarter of fiscal 2021 of $21.6 million. For the remaining 2025 Senior Notes holders who participated in the refinancing, these transactions were accounted for as modifications because on a creditor-by-creditor basis the present value of the cash flows between the debt instruments before and after the transaction was less than 10%. The Company recorded a portion of the transaction expenses of $5.8 million to interest expense pursuant to ASC 470, subtopic 50-40. The remaining debt issuance costs of $7.9 million and debt discount of $6.4 million related to the modified debt is being amortized over the new term of the 2029 Senior Notes using the effective interest method. 2028 Senior Notes As of June 25, 2022, the Company had Senior Notes due 2028 outstanding in the aggregate principal balance of $400 million. The 2028 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company's domestic subsidiaries and mature on February 1, 2028. 2029 Senior Notes As of June 25, 2022, the Company had 2029 Senior Notes due 2029 outstanding in the aggregate principal balance of $950 million. The 2029 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company's domestic subsidiaries and mature on February 15, 2029. Interest expense for the 2029 Senior Notes, 2028 Senior Notes and 2025 Senior Notes was as follows: Three Months Ended Nine Months Ended Interest Rate June 25, 2022 June 26, 2021 June 25, 2022 June 26, 2021 2025 Senior Notes 4.375 % $ — $ — $ — $ 2.3 2028 Senior Notes 4.625 % 4.8 4.8 14.4 14.4 2029 Senior Notes 3.250 % 8.2 8.2 24.6 24.5 Total $ 13.0 $ 13.0 $ 39.0 $ 41.2 Accounts Receivable Securitization Program During April 2022, the Company repaid the outstanding balance of $248.5 million under the accounts receivable securitization program (the "Securitization Program"). On June 10, 2022, the Company amended the Credit and Security agreement with lenders, temporarily suspending the ability to borrow and the need to comply with covenants for up to a year. As of June 25, 2022, the Company did not have any borrowings under this program. Other Other represents debt acquired in the Mobidiag acquisition, which was primarily with the European Investment Bank ("EIB"). Multiple tranches were withdrawn under the agreement and were primarily used to fund research and development projects and expansion efforts. The debt agreement contained change-in-control provisions allowing the EIB to call the debt at any time after a change-in-control, which occurred as a result of Hologic acquiring Mobidiag. The tranches withdrawn under this agreement had interest rates ranging from 6.0% to 7.0%. The debt agreement included additional payments to the EIB based on revenues generated by products developed under the funding as well as prepayment penalties. During the first quarter of fiscal 2022, the Company paid off the outstanding debt obligation of $63.7 million, and the debt agreement with the EIB was terminated.

Derivatives

Derivatives	9 Months Ended
	Jun. 25, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives Interest Rate Swap - Cash Flow Hedge The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk through the use of interest rate swaps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income ("AOCI") to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. To the extent there is any hedge ineffectiveness, changes in fair value relating to the ineffective portion are immediately recognized in earnings in other income (expense), net in the Consolidated Statements of Income. In fiscal 2019, in order to hedge a portion of its variable rate debt, the Company entered into an interest rate swap contract with an effective date of December 23, 2020 and a termination date of December 17, 2023. The notional amount of this swap is $1.0 billion. The interest rate swap effectively fixes the LIBOR component of the variable interest rate on $1.0 billion of the notional amount under the 2021 Credit Agreement at 1.23%. The critical terms of the interest rate swap are designed to mirror the terms of the Company’s LIBOR-based borrowings under its credit agreement and therefore are highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the LIBOR-based interest payments on $1.0 billion of principal. Therefore, changes in the fair value of the swap are recorded in AOCI. The fair value of this derivative was in an asset position of $28.6 million as of June 25, 2022. Forward Foreign Currency Contracts and Foreign Currency Option Contracts The Company enters into forward foreign currency exchange contracts and foreign currency option contracts to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company's cash and operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the UK Pound, the Australian dollar, the Canadian dollar, the Chinese Yuan and the Japanese Yen. These foreign currency exchange contracts are entered into to support transactions made in the ordinary course of business and are not speculative in nature. The contracts are generally for periods of one year or less. The Company did not elect hedge accounting for these contracts. The change in the fair value of these contracts is recognized directly in the Consolidated Statements of Income as a component of other income (expense), net. Realized and unrealized gains and losses from these contracts, which were the only derivative contracts not designated for hedge accounting, for the three and nine months ended June 25, 2022 and June 26, 2021, respectively, were as follows: Three Months Ended Nine Months Ended June 25, 2022 June 26, 2021 June 25, 2022 June 26, 2021 Amount of realized gain (loss) recognized in income Forward foreign currency contracts $ 19.6 $ (7.0) $ 42.4 $ (6.5) Foreign currency option contracts — (1.4) — (4.4) $ 19.6 $ (8.4) $ 42.4 $ (10.9) Amount of unrealized gain (loss) recognized in income Forward foreign currency contracts $ 2.5 $ 1.5 $ 9.2 $ (2.0) Foreign currency option contracts — 0.4 — (5.5) $ 2.5 $ 1.9 $ 9.2 $ (7.5) Amount of gain (loss) recognized in income Total $ 22.1 $ (6.5) $ 51.6 $ (18.4) As of June 25, 2022, the Company had outstanding forward foreign currency contracts that were not designated for hedge accounting and are used to hedge fluctuations in the U.S. dollar of certain of the Company's cash balances denominated in the Euro and UK pound, as well as forecasted transactions denominated in the Euro, UK Pound, Australian Dollar, Canadian Dollar, Chinese Yuan and Japanese Yen with an aggregate notional amount of $330.2 million. Financial Instrument Presentation The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the balance sheet as of June 25, 2022: Balance Sheet Location June 25, 2022 September 25, 2021 Assets: Derivative instruments designated as a cash flow hedge: Interest rate swap contract Prepaid expenses and other current assets $ 19.0 $ — Interest rate swap contract Other assets 9.6 — $ 28.6 $ — Derivatives not designated as hedging instruments: Forward foreign currency contracts Prepaid expenses and other current assets $ 10.3 $ 1.7 $ 10.3 $ 1.7 Liabilities: Derivative instruments designated as a cash flow hedge: Interest rate swap contract Accrued expenses $ — $ 11.1 Interest rate swap contract Other long-term liabilities — 7.6 Total $ — $ 18.7 Derivatives not designated as hedging instruments: Forward foreign currency contracts Accrued expenses $ — $ 0.6 The following table presents the unrealized gain (loss) recognized in AOCI related to the interest rate caps and interest rate swap for the following reporting periods: Three Months Ended Nine Months Ended June 25, 2022 June 26, 2021 June 25, 2022 June 26, 2021 Amount of gain (loss) recognized in other comprehensive income, net of taxes: Interest rate swap $ 8.4 $ 3.0 $ 35.7 $ 8.2 Interest rate cap agreements — — — (0.2) Total $ 8.4 $ 3.0 $ 35.7 $ 8.0

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Jun. 25, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Litigation and Related Matters On November 6, 2015, the Company filed a suit against Minerva Surgical, Inc. (“Minerva”) in the United States District Court for the District of Delaware, alleging that Minerva’s endometrial ablation device infringes U.S. Patent 6,872,183 (the '183 patent), U.S. Patent 8,998,898 and U.S. Patent 9,095,348 (the '348 patent). On January 25, 2016, the Company amended the complaint to include claims against Minerva for unfair competition, deceptive trade practices and tortious interference with business relationships. On February 5, 2016, the Company filed a second amended complaint to additionally allege that Minerva’s endometrial ablation device infringes U.S. Patent 9,247,989 (the '989 patent). On March 4, 2016, Minerva filed an answer and counterclaims against the Company, seeking declaratory judgment on the Company’s claims and asserting claims against the Company for unfair competition, deceptive trade practices, interference with contractual relationships, breach of contract and trade libel. On June 2, 2016, the Court denied the Company’s motion for a preliminary injunction on its patent claims and denied Minerva’s request for preliminary injunction related to the Company’s alleged false and deceptive statements regarding the Minerva product. On June 28, 2018, the Court granted the Company's summary judgment motions on infringement and no invalidity with respect to the ‘183 and ‘348 patents. The Court also granted the Company’s motion for summary judgment on assignor estoppel, which bars Minerva’s invalidity defenses. The Court also denied all of Minerva’s defenses, including its motions for summary judgment on invalidity, non-infringement, no willfulness, and no unfair competition. On July 27, 2018, after a two-week trial, a jury returned a verdict that: (1) awarded the Company $4.8 million in damages for Minerva’s infringement; (2) found that Minerva’s infringement was not willful; and (3) found for the Company regarding Minerva’s counterclaims. Damages continued to accrue as Minerva continues its infringing conduct. On May 2, 2019, the Court issued rulings that denied the parties' post-trial motions, including the Company's motion for a permanent injunction seeking to prohibit Minerva from selling infringing devices. Both parties appealed the Court's rulings regarding the post-trial motions. On March 4, 2016, Minerva filed two petitions at the United States Patent and Trademark Office ("USPTO") for inter partes review of the '348 patent. On September 12, 2016, the Patent Trial and Appeal Board of the USPTO (“PTAB") declined both petitions to review patentability of the '348 patent. On April 11, 2016, Minerva filed a petition for inter partes review of the '183 patent. On October 6, 2016, the PTAB granted the petition and instituted a review of the '183 patent. On December 15, 2017, the PTAB issued a final written decision invalidating all claims of the ‘183 patent. On February 9, 2018, the Company appealed this decision to the United States Court of Appeals for the Federal Circuit ("Court of Appeals"). On April 19, 2019, the Court of Appeals affirmed the PTAB's final written decision regarding the '183 patent. On July 16, 2019, the Court of Appeals denied the Company’s petition for rehearing in the appeal regarding the '183 patent. On April 22, 2020, the Court of Appeals affirmed the district court’s summary judgment ruling in favor of the Company of no invalidity and infringement, and summary judgment that assignor estoppel bars Minerva from challenging the validity of the ‘348 patent. The Court of Appeals also denied the Company’s motion for a permanent injunction and ongoing royalties for infringement of the ‘183 patent. The Court of Appeals denied Minerva’s arguments for no damages or, alternatively, a new trial. On May 22, 2020 both parties petitioned for en banc review of the Court of Appeals decision. On July 22, 2020, the Court of Appeals denied both parties' petitions for en banc review. On August 28, 2020, the district court entered final judgment against Minerva but stayed execution pending resolution of Minerva’s petition for Supreme Court review. On September 30, 2020, Minerva filed a petition requesting Supreme Court review on the issue of assignor estoppel. On November 5, 2020, the Company filed a cross-petition requesting Supreme Court review on the issue of assignor estoppel. On January 8, 2021, the Supreme Court granted Minerva’s petition to address the issue of assignor estoppel and denied the Company's petition. Oral argument before the Supreme Court was held on April 21, 2021. On June 29, 2021, the Supreme Court ruled 5-4 to uphold the assignor estoppel but limited its application to situations in which an assignor’s claim of invalidity contradicts a prior representation the assignor made in assigning the patent. The Court also vacated the ruling of the Court of Appeals and remanded the case for further proceedings consistent with its opinion. An oral argument before the Court of Appeals was held January 27, 2022 and the parties are awaiting a decision. On April 11, 2017, Minerva filed suit against the Company and Cytyc Surgical Products, LLC (“Cytyc”) in the United States District Court for the Northern District of California alleging that the Company’s and Cytyc’s NovaSure ADVANCED endometrial ablation device infringes Minerva’s U.S. patent 9,186,208 (the '208 patent). Minerva is seeking a preliminary and permanent injunction against the Company and Cytyc from selling this NovaSure device as well as enhanced damages and interest, including lost profits, price erosion and/or royalty. On January 5, 2018, the Court denied Minerva's motion for a preliminary injunction. On February 2, 2018, at the parties’ joint request, this action was transferred to the District of Delaware. On March 26, 2019, the Magistrate Judge issued a claims construction ruling regarding the disputed terms in the patent, which the District Court Judge adopted in all respects on October 21, 2019. On July 27, 2021, the Delaware district court granted the Company’s motion for summary judgment on invalidity of the '208 patent and entered judgment in favor of the Company. On August 24, 2021, Minerva appealed this and the other rulings to the Court of Appeals. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses. In connection with the 2019 divestiture of its Medical Aesthetics business, the Company agreed to indemnify Clayton Dubilier & Rice for certain legal matters that existed at the date of disposition. This included payment of an $8.5 million settlement in resolution of a 2016 complaint filed by ARcare, Inc. against Cynosure, Inc., alleging violations of the Telephone Consumer Protection Act. Following court approval on June 6, 2022, the Company made a final payment of $8.5 million, which was previously accrued, on behalf of Cynosure, Inc. to close out its indemnification obligation on the matter. There are currently no further accruals related to the Company’s indemnification obligations under the Medical Aesthetic business divestiture agreements. The Company is a party to various other legal proceedings and claims arising out of the ordinary course of its business. The Company believes that except for those matters described above there are no other proceedings or claims pending against it the ultimate resolution of which could have a material adverse effect on its financial condition or results of operations. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies (ASC 450). Legal costs are expensed as incurred.

Net Income (Loss) Per Share

Net Income (Loss) Per Share	9 Months Ended
	Jun. 25, 2022
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Net Income Per Share A reconciliation of basic and diluted share amounts is as follows: Three Months Ended Nine Months Ended June 25, June 26, June 25, June 26, Basic weighted average common shares outstanding 250,756 256,230 251,943 257,769 Weighted average common stock equivalents from assumed exercise of stock options and issuance of restricted stock units 2,337 2,351 2,330 2,602 Diluted weighted average common shares outstanding 253,093 258,581 254,273 260,371 Weighted-average anti-dilutive shares related to: Outstanding stock options and restricted stock units 1,066 653 1,021 515

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Jun. 25, 2022
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The following presents stock-based compensation expense in the Company’s Consolidated Statements of Income: Three Months Ended Nine Months Ended June 25, June 26, June 25, June 26, Cost of revenues $ 2.2 $ 1.9 $ 7.1 $ 6.4 Research and development 1.8 1.4 7.3 6.2 Selling and marketing 2.6 2.3 8.0 7.7 General and administrative 8.7 8.9 29.4 29.8 Restructuring — 0.9 — 0.9 $ 15.3 $ 15.4 $ 51.8 $ 51.0 The Company granted options to purchase 0.7 million and 0.6 million shares of the Company's common stock during the nine months ended June 25, 2022 and June 26, 2021, respectively, with weighted-average exercise prices of $71.12 and $68.62, respectively. There were 4.4 million options outstanding at June 25, 2022 with a weighted-average exercise price of $48.49. The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table: Three Months Ended Nine Months Ended June 25, June 26, June 25, June 26, Risk-free interest rate 1.1 % 0.4 % 1.1 % 0.4 % Expected volatility 34.2 % 35.0 % 34.2 % 35.0 % Expected life (in years) 4.8 4.8 4.8 4.8 Dividend yield — — — — Weighted average fair value of options granted $ 21.48 $ 19.17 $ 21.03 $ 20.07 The Company granted 0.6 million and 0.5 million restricted stock units ("RSUs") during the nine months ended June 25, 2022 and June 26, 2021, respectively, with weighted-average grant date fair values of $71.18 and $68.45 per unit, respectively. In addition, the Company granted 0.1 million and 0.1 million performance stock units ("PSUs") during the nine months ended June 25, 2022 and June 26, 2021, respectively, to members of its senior management team, which have a weighted-average grant date fair value of $71.16 and $68.51 per unit, respectively. Each recipient of PSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of three years provided the Company’s defined Return on Invested Capital metrics are achieved. The Company also granted 0.1 million and 0.1 million of PSUs based on a three-year cumulative free cash flow measure ("FCF PSUs") to its senior management team, which had a grant date fair value of $71.16 and $68.51 per unit during the nine months ended June 25, 2022 and June 26, 2021, respectively. Each recipient of FCF PSUs is eligible to receive between zero and 200% of the target number of shares of the Company's common stock at the end of the three-year measurement period. The PSUs and FCF PSUs cliff-vest three years from the date of grant, and the Company recognizes compensation expense ratably over the required service period based on its estimate of the number of shares that will vest upon achieving the measurement criteria. If there is a change in the estimate of the number of shares that are probable of vesting, the Company will cumulatively adjust compensation expense in the period that the change in estimate is made. The Company also granted 0.1 million and 0.1 million market-based awards ("MSUs") to its senior management team during the nine months ended June 25, 2022 and June 26, 2021, respectively. Each recipient of MSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of three years based upon achieving a certain total shareholder return relative to a defined peer group. The MSUs were valued at $75.43 and $82.31 per share using the Monte Carlo simulation model in fiscal 2022 and 2021, respectively. The MSUs cliff-vest three years from the date of grant, and the Company recognizes compensation expense for the MSUs ratably over the service period. At June 25, 2022, there was 1.7 million in aggregate unvested RSUs, PSUs, FCF PSUs and MSUs outstanding. At June 25, 2022, there was $18.4 million and $67.4 million of unrecognized compensation expense related to stock options and stock units (comprised of RSUs, PSUs, FCF PSUs and MSUs), respectively, to be recognized over a weighted-average period of 2.3 and 2.0 years, respectively.

Other Balance Sheet Information

Other Balance Sheet Information	9 Months Ended
	Jun. 25, 2022
Balance Sheet Related Disclosures [Abstract]
Other Balance Sheet Information	Other Balance Sheet Information June 25, September 25, Inventories Raw materials $ 228.9 $ 163.3 Work-in-process 59.5 53.0 Finished goods 292.8 284.9 $ 581.2 $ 501.2 Property, plant and equipment Equipment $ 414.7 $ 467.1 Equipment under customer usage agreements 492.5 484.6 Building and improvements 196.2 191.2 Leasehold improvements 51.0 49.7 Land 41.1 41.3 Furniture and fixtures 17.5 16.8 Finance lease right of use asset 8.2 9.9 $ 1,221.2 $ 1,260.6 Less – accumulated depreciation and amortization (731.1) (695.9) $ 490.1 $ 564.7

Business Segments and Geographi

Business Segments and Geographic Information	9 Months Ended
	Jun. 25, 2022
Segment Reporting [Abstract]
Business Segments and Geographic Information	Business Segments and Geographic InformationThe Company has four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, goodwill and intangible asset impairment charges, transaction and integration expenses for acquisitions, restructuring, consolidation and divestiture charges, litigation charges, and other one-time or unusual items. Each segment's operating results include its share of allocated corporate administrative expenses. Identifiable assets for the reportable segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no inter-segment revenues during the three and nine months ended June 25, 2022 and June 26, 2021. Segment information is as follows: Three Months Ended Nine Months Ended June 25, June 26, June 25, June 26, Total revenues: Diagnostics $ 560.1 $ 665.5 $ 2,497.6 $ 2,858.2 Breast Health 282.8 349.0 952.7 1,018.0 GYN Surgical 138.1 127.9 389.6 366.2 Skeletal Health 21.7 25.9 69.7 73.3 $ 1,002.7 $ 1,168.3 $ 3,909.6 $ 4,315.7 Income (loss) from operations: Diagnostics $ 175.0 $ 260.1 $ 1,247.4 $ 1,745.1 Breast Health 32.0 81.0 163.1 235.1 GYN Surgical 60.1 18.2 92.4 60.5 Skeletal Health (3.2) (0.7) (3.6) 0.1 $ 263.9 $ 358.6 $ 1,499.3 $ 2,040.8 Depreciation and amortization: Diagnostics $ 67.8 $ 63.9 $ 205.4 $ 179.4 Breast Health 16.9 13.6 45.5 39.7 GYN Surgical 24.7 23.2 72.1 69.5 Skeletal Health 0.2 0.2 0.5 0.5 $ 109.6 $ 100.9 $ 323.5 $ 289.1 Capital expenditures: Diagnostics $ 19.8 $ 35.7 $ 77.3 $ 113.2 Breast Health 2.2 4.5 9.2 10.1 GYN Surgical 2.8 3.0 6.9 9.5 Skeletal Health 0.1 0.2 0.3 0.2 Corporate 0.8 — 1.9 1.0 $ 25.7 $ 43.4 $ 95.6 $ 134.0 June 25, September 25, Identifiable assets: Diagnostics $ 3,029.8 $ 3,348.8 Breast Health 1,244.0 1,233.9 GYN Surgical 1,488.2 1,369.7 Skeletal Health 25.8 31.9 Corporate 3,569.6 2,935.6 $ 9,357.4 $ 8,919.9 The Company had no customers that represented greater than 10% of consolidated revenues during the three and nine months ended June 25, 2022 and June 26, 2021. The Company operates in the following major geographic areas noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from France, the United Kingdom and Germany. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of World” designation includes Canada, Latin America and the Middle East. Revenues by geography as a percentage of total revenues were as follows: Three Months Ended Nine Months Ended June 25, June 26, June 25, June 26, United States 73.3 % 64.2 % 70.1 % 68.4 % Europe 16.4 % 24.7 % 19.2 % 22.3 % Asia-Pacific 7.1 % 7.7 % 7.7 % 6.2 % Rest of World 3.2 % 3.4 % 3.0 % 3.1 % 100.0 % 100.0 % 100.0 % 100.0 %

Income Taxes

Income Taxes	9 Months Ended
	Jun. 25, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes In accordance with ASC 740, Income Taxes , each interim period is considered integral to the annual period, and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period. The Company’s effective tax rates for the three and nine months ended June 25, 2022 were 8.1% and 18.1%, respectively, compared to 20.6% and 21.0%, respectively, for the corresponding periods in the prior year. The effective tax rates for the three and nine months ended June 25, 2022 were lower than the U.S. statutory tax rate primarily due to the impact of the U.S. deduction for foreign derived intangible income, reserve releases resulting from statute of limitations expirations, and the geographic mix of income earned by our international subsidiaries, which are taxed at rates lower than the U.S. statutory tax rate, partially offset by state income taxes. The effective tax rate for the three months ended June 26, 2021 was lower than the U.S. statutory tax rate primarily due to the impact of the U.S. deduction for foreign derived intangible income, the geographic mix of income earned by our international subsidiaries, which are taxed at rates lower than the U.S. statutory tax rate, and federal and state tax credits, partially offset by state income taxes. The effective tax rate for the nine months ended June 26, 2021 was equal to the U.S. statutory tax rate as the impact of the U.S. deduction for foreign derived intangible income and the geographic mix of income earned by our international subsidiaries, which are taxed at rates lower than the U.S. statutory tax rate, was offset by state income taxes. Through the third quarter of fiscal 2022, the Company received $422.6 million in refunds related to federal and state carryback claims, including interest. Non-Income Tax Matters The Company is subject to tax examinations for value-added, sales-based, payroll, and other non-income tax items. A number of these examinations are ongoing in various jurisdictions. The Company takes certain non-income tax positions in the jurisdictions in which it operates. In the normal course of business, the Company's positions and conclusions related to its non-income tax positions could be challenged, resulting in assessments by governmental authorities. Pursuant to ASC 450, the Company has recorded loss contingencies with respect to some of these positions. While the Company believes its estimated losses recorded are reasonable, certain audits are still ongoing and additional charges could be recorded in the future. In January 2022, the Company settled a state non-income tax audit for fiscal years 2016-2017 for $5.4 million, which was previously accrued. In the third quarter of fiscal 2022, the Company reversed $5.2 million in non-income tax reserves related to tax credits received for research and development expenditures for calendar years 2018-2020 as a result of a foreign non-income tax audit settlement finalized in July 2022.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	9 Months Ended
	Jun. 25, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	Intangible Assets Intangible assets consisted of the following: Description As of June 25, 2022 As of September 25, 2021 Gross Accumulated Gross Accumulated Acquired intangible assets: Developed technology $ 4,605.7 $ 3,389.8 $ 4,597.7 $ 3,184.2 In-process research and development 64.5 — 71.6 — Customer relationships 607.9 530.9 591.7 510.1 Trade names 267.1 200.0 268.1 191.8 Non-competition agreements 1.4 1.4 1.5 1.5 Business licenses 2.4 2.4 2.5 2.5 Total acquired intangible assets $ 5,549.0 $ 4,124.5 $ 5,533.1 $ 3,890.1 Internal-use software 23.6 17.5 23.5 17.2 Capitalized software embedded in products 26.1 20.2 25.5 15.6 Total intangible assets $ 5,598.7 $ 4,162.2 $ 5,582.1 $ 3,922.9 The estimated remaining amortization expense of the Company's acquired intangible assets as of June 25, 2022 for each of the five succeeding fiscal years was as follows: Remainder of Fiscal 2022 $ 86.2 Fiscal 2023 $ 236.6 Fiscal 2024 $ 227.6 Fiscal 2025 $ 213.1 Fiscal 2026 $ 178.8

Product Warranties

Product Warranties	9 Months Ended
	Jun. 25, 2022
Guarantees [Abstract]
Product Warranties	Product Warranties Product warranty activity was as follows: Balance at Provisions Acquired Settlements/ Balance at Nine Months Ended: June 25, 2022 $ 8.8 $ 5.1 $ — $ (5.3) $ 8.6 June 26, 2021 $ 9.9 $ 6.1 $ 0.3 $ (6.7) $ 9.6

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	9 Months Ended
	Jun. 25, 2022
Accumulated Other Comprehensive Income [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss The following tables summarize the changes in accumulated balances of other comprehensive loss for the periods presented: Three Months Ended June 25, 2022 Nine Months Ended June 25, 2022 Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Beginning Balance $ (115.4) $ (1.3) $ 12.6 $ (104.1) $ (43.1) $ (1.3) $ (14.7) $ (59.1) Other comprehensive income (loss) before reclassifications (52.0) — 8.4 (43.6) (124.3) — 35.7 (88.6) Ending Balance $ (167.4) $ (1.3) $ 21.0 $ (147.7) $ (167.4) $ (1.3) $ 21.0 $ (147.7) Three Months Ended June 26, 2021 Nine Months Ended June 26, 2021 Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Foreign Currency Translation Pension Plans Hedged Interest Rate Caps Hedged Interest Rate Swaps Total Beginning Balance $ (14.5) $ (1.8) $ (19.5) $ (35.8) $ (22.9) $ (1.8) $ (0.9) $ (24.1) $ (49.7) Other comprehensive income (loss) before reclassifications (9.4) — 3.0 (6.4) (1.0) — 0.4 7.6 7.0 Amounts reclassified to statement of income — — — — — — 0.5 — 0.5 Ending Balance $ (23.9) $ (1.8) $ (16.5) $ (42.2) $ (23.9) $ (1.8) $ — $ (16.5) $ (42.2)

Share Repurchase

Share Repurchase	9 Months Ended
	Jun. 25, 2022
Equity [Abstract]
Share Repurchase	Share RepurchaseOn December 9, 2020, the Company's Board of Directors authorized a new five-year share repurchase plan to repurchase up to $1.0 billion of the Company's outstanding common stock. The prior plan was terminated in connection with this new authorization. During the nine month ended June 25, 2022, the Company repurchased 5.2 million shares of its common stock for total consideration of $367.0 million. There were no share repurchases in the third quarter of fiscal 2022. As of June 25, 2022, $324.7 million remained available under this authorization.

New Accounting Pronouncements

New Accounting Pronouncements	9 Months Ended
	Jun. 25, 2022
Accounting Policies [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The FASB issued this Update as part of its initiative to reduce complexity in accounting standards (the Simplification Initiative). For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and are applicable to the Company in fiscal 2022. The adoption of ASU No. 2019-12 did not have a material impact on the Company's consolidated financial position and results of operations. In January 2020, the FASB issued ASU No. 2020-01, Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) . The FASB issued this Update to clarify certain interactions between the guidance to account for certain equity securities under Topic 321, the guidance to account for investments under the equity method of accounting in Topic 323, and the guidance in Topic 815. This update could change how an entity accounts for an equity security under the measurement alternative or a forward contract or purchased option to purchase securities that, upon settlement of the forward contract or exercise of the purchased option, would be accounted for under the equity method of accounting or the fair value option in accordance with Topic 825, Financial Instruments . For entities that have adopted the amendments in Update 2020-01, the updated guidance is effective for annual periods beginning after December 15, 2020, and is applicable to the Company in fiscal 2022. The adoption of ASU No. 2020-01 did not have a material impact on the Company's consolidated financial position and results of operations. In January 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848) . The FASB issued this Update as optional guidance for a limited period of time to ease the potential burden in accounting for or recognizing the effects of reference rate reform on financial reporting. This update will provide optional expedients and exceptions for applying GAAP to only contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. For entities that have adopted the amendments in Update 2020-04, the updated guidance is effective for all entities as of March 12, 2020 through December 31, 2022. The Company adopted ASU 2020-04 in the first quarter of fiscal 2022, which did not have a material impact on the Company's consolidated financial position and results of operations. In January 2021, FASB issued ASU No. 2021-01, Reference Rate Reform (Topic 848) Scope. The FASB issued this Update in response to stakeholder concerns about potential diversity in practice. The FASB decided to clarify the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions in Topic 848. This update provides optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to only contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. For entities that have adopted the amendments in Update 2021-01, the updated guidance is effective for all entities immediately as of January 2021. The Company adopted ASU 2021-01 in the first quarter of fiscal 2022, which did not have a material impact on the Company's consolidated financial position and results of operations. In May 2021, the FASB issued ASU No. 2021-05, Leases (Topic 842), Lessors - Certain Leases with Variable Lease Payments . This Update addresses an issue related to a lessor's accounting for certain leases with variable lease payments. The amendments in this Update affect lessors with lease contracts that (1) have variable lease payments that do not depend on a reference index or a rate and (2) would have resulted in the recognition of a selling loss at lease commencement if classified as a sales-type lease or a direct financing lease. The Company adopted the amendments in ASU No. 2021-05 in the first quarter of fiscal 2022, which did not have a material effect on the Company's consolidated financial statements.

New Accounting Pronouncements (

New Accounting Pronouncements (Policies)	9 Months Ended
	Jun. 25, 2022
Accounting Policies [Abstract]
New Accounting Pronouncements	In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The FASB issued this Update as part of its initiative to reduce complexity in accounting standards (the Simplification Initiative). For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and are applicable to the Company in fiscal 2022. The adoption of ASU No. 2019-12 did not have a material impact on the Company's consolidated financial position and results of operations. In January 2020, the FASB issued ASU No. 2020-01, Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) . The FASB issued this Update to clarify certain interactions between the guidance to account for certain equity securities under Topic 321, the guidance to account for investments under the equity method of accounting in Topic 323, and the guidance in Topic 815. This update could change how an entity accounts for an equity security under the measurement alternative or a forward contract or purchased option to purchase securities that, upon settlement of the forward contract or exercise of the purchased option, would be accounted for under the equity method of accounting or the fair value option in accordance with Topic 825, Financial Instruments . For entities that have adopted the amendments in Update 2020-01, the updated guidance is effective for annual periods beginning after December 15, 2020, and is applicable to the Company in fiscal 2022. The adoption of ASU No. 2020-01 did not have a material impact on the Company's consolidated financial position and results of operations. In January 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848) . The FASB issued this Update as optional guidance for a limited period of time to ease the potential burden in accounting for or recognizing the effects of reference rate reform on financial reporting. This update will provide optional expedients and exceptions for applying GAAP to only contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. For entities that have adopted the amendments in Update 2020-04, the updated guidance is effective for all entities as of March 12, 2020 through December 31, 2022. The Company adopted ASU 2020-04 in the first quarter of fiscal 2022, which did not have a material impact on the Company's consolidated financial position and results of operations. In January 2021, FASB issued ASU No. 2021-01, Reference Rate Reform (Topic 848) Scope. The FASB issued this Update in response to stakeholder concerns about potential diversity in practice. The FASB decided to clarify the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions in Topic 848. This update provides optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to only contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. For entities that have adopted the amendments in Update 2021-01, the updated guidance is effective for all entities immediately as of January 2021. The Company adopted ASU 2021-01 in the first quarter of fiscal 2022, which did not have a material impact on the Company's consolidated financial position and results of operations. In May 2021, the FASB issued ASU No. 2021-05, Leases (Topic 842), Lessors - Certain Leases with Variable Lease Payments . This Update addresses an issue related to a lessor's accounting for certain leases with variable lease payments. The amendments in this Update affect lessors with lease contracts that (1) have variable lease payments that do not depend on a reference index or a rate and (2) would have resulted in the recognition of a selling loss at lease commencement if classified as a sales-type lease or a direct financing lease. The Company adopted the amendments in ASU No. 2021-05 in the first quarter of fiscal 2022, which did not have a material effect on the Company's consolidated financial statements.

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Jun. 25, 2022
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis: Three Months Ended June 25, 2022 Three Months Ended June 26, 2021 Business ( in millions ) United States International Total United States International Total Diagnostics: Cytology & Perinatal $ 74.3 $ 41.6 $ 115.9 $ 73.9 $ 42.0 $ 115.9 Molecular Diagnostics 304.2 131.1 435.3 270.1 266.3 536.4 Blood Screening 8.9 — 8.9 13.2 — 13.2 Total $ 387.4 $ 172.7 $ 560.1 $ 357.2 $ 308.3 $ 665.5 Breast Health: Breast Imaging $ 165.5 $ 46.7 $ 212.2 $ 218.4 $ 61.9 $ 280.3 Interventional Breast Solutions 56.8 13.8 70.6 54.8 13.9 68.7 Total $ 222.3 $ 60.5 $ 282.8 $ 273.2 $ 75.8 $ 349.0 GYN Surgical $ 112.2 $ 25.9 $ 138.1 $ 103.9 $ 24.0 $ 127.9 Skeletal Health $ 12.7 $ 9.0 $ 21.7 $ 15.6 $ 10.3 $ 25.9 $ 734.6 $ 268.1 $ 1,002.7 $ 749.9 $ 418.4 $ 1,168.3 Nine Months Ended June 25, 2022 Nine Months Ended June 26, 2021 Business (in millions) United States International Total United States International Total Diagnostics: Cytology & Perinatal $ 227.4 $ 134.6 $ 362.0 $ 230.8 $ 127.1 $ 357.9 Molecular Diagnostics 1,395.9 715.2 2,111.1 1,561.7 905.3 2,467.0 Blood Screening 24.5 — 24.5 33.3 — 33.3 Total $ 1,647.8 $ 849.8 $ 2,497.6 $ 1,825.8 $ 1,032.4 $ 2,858.2 Breast Health: Breast Imaging $ 561.8 $ 177.7 $ 739.5 $ 619.5 $ 198.3 $ 817.8 Interventional Breast Solutions 171.1 42.1 213.2 164.9 35.3 200.2 Total $ 732.9 $ 219.8 $ 952.7 $ 784.4 $ 233.6 $ 1,018.0 GYN Surgical $ 315.4 $ 74.2 $ 389.6 $ 296.8 $ 69.4 $ 366.2 Skeletal Health $ 43.3 $ 26.4 $ 69.7 $ 44.7 $ 28.6 $ 73.3 $ 2,739.4 $ 1,170.2 $ 3,909.6 $ 2,951.7 $ 1,364.0 $ 4,315.7 Three Months Ended Nine Months Ended Geographic Regions ( in millions ) June 25, 2022 June 26, 2021 June 25, 2022 June 26, 2021 United States $ 734.6 $ 749.9 $ 2,739.4 $ 2,951.7 Europe 164.5 289.0 750.8 963.9 Asia-Pacific 71.7 89.6 301.1 268.1 Rest of World 31.9 39.8 118.3 132.0 $ 1,002.7 $ 1,168.3 $ 3,909.6 $ 4,315.7 The following table provides revenue recognized by source: Three Months Ended Nine Months Ended Revenue by type (in millions) June 25, 2022 June 26, 2021 June 25, 2022 June 26, 2021 Disposables $ 713.0 $ 797.7 $ 2,930.5 $ 3,239.2 Capital equipment, components and software 124.1 197.5 478.2 590.2 Service 160.8 158.4 486.2 437.2 Other 4.8 14.7 14.7 49.1 $ 1,002.7 $ 1,168.3 $ 3,909.6 $ 4,315.7

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Jun. 25, 2022
Fair Value Disclosures [Abstract]
Fair Value Assets and Liabilities Measured on Recurring Basis	Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at June 25, 2022: Fair Value at Reporting Date Using Balance as of June 25, 2022 Quoted Prices in Significant Significant Assets: Interest rate swap $ 28.6 $ — $ 28.6 $ — Forward foreign currency contracts 10.3 — 10.3 — Total $ 38.9 $ — $ 38.9 $ — Liabilities: Contingent consideration $ 23.4 $ — $ — $ 23.4 Total $ 23.4 $ — $ — $ 23.4 Liabilities Measured and Recorded at Fair Value on a Recurring Basis Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of contingent consideration liabilities, during the three and nine month periods ended June 25, 2022 and June 26, 2021 were as follows: Three Month Ended Nine Months Ended June 25, 2022 June 26, 2021 June 25, 2022 June 26, 2021 Balance at beginning of period $ 58.8 $ 71.7 $ 75.1 $ 81.8 Contingent consideration recorded at acquisition — — — — Fair value adjustments (35.4) — (39.5) (10.1) Payments — — (12.2) — Balance at end of period $ 23.4 $ 71.7 $ 23.4 $ 71.7

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Jun. 25, 2022
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The total purchase price was allocated to Bolder's preliminary tangible and identifiable intangible assets and liabilities based on the estimated fair values as of November 29, 2021, as set forth below. Cash $ 1.9 Accounts receivable 1.3 Inventory 3.3 Other assets 3.0 Accounts payable and accrued expenses (3.2) Identifiable intangible assets: Developed technology 73.6 Customer relationship 21.7 Trade names 1.4 Deferred income taxes, net (13.8) Goodwill 70.9 Purchase Price $ 160.1 The total purchase price was allocated to Mobidiag's tangible and identifiable intangible assets and liabilities based on the estimated fair values as of June 17, 2021, as set forth below. Cash $ 7.0 Accounts receivable 4.2 Inventory 12.1 Other assets 29.6 Accounts payable and accrued expenses (16.5) Other liabilities (12.2) Identifiable intangible assets: Developed technology 285.0 In-process research and development 74.0 Customer relationships 20.9 Trade names 20.0 Long-term debt (66.1) Deferred income taxes, net (56.1) Goodwill 427.7 Purchase Price $ 729.6 The total purchase price was allocated to Biotheranostics' tangible and identifiable intangible assets and liabilities based on the estimated fair values as of February 22, 2021, as set forth below. Cash $ 9.6 Accounts receivable 6.6 Other assets 6.5 Accounts payable and accrued expenses (8.2) Other liabilities (8.1) Identifiable intangible assets: Developed technology 160.3 Trade names 2.1 Deferred income taxes, net (18.4) Goodwill 80.9 Purchase Price $ 231.3 Cash $ 5.6 Accounts receivable 9.3 Inventory 9.0 Other assets 13.9 Accounts payable and accrued expenses (16.7) Other liabilities (9.2) Identifiable intangible assets: Developed technology 69.8 Customer relationships 9.2 Deferred income taxes, net (19.3) Goodwill 83.5 Purchase Price $ 155.1

Trade Receivables and Allowan_2

Trade Receivables and Allowance for Credit Losses (Tables)	9 Months Ended
	Jun. 25, 2022
Receivables [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable	The following is a rollforward of the allowance for credit losses as of June 25, 2022 compared to June 26, 2021:

Borrowings and Credit Arrange_2

Borrowings and Credit Arrangements (Tables)	9 Months Ended
	Jun. 25, 2022
Debt Disclosure [Abstract]
Company's Borrowings	The Company’s borrowings consisted of the following: June 25, September 25, Current debt obligations, net of debt discount and deferred issuance costs: Term Loan $ 7.5 $ — Securitization Program — 248.5 Other — 64.5 Total current debt obligations $ 7.5 $ 313.0 Long-term debt obligations, net of debt discount and issuance costs: Term Loan 1,482.6 1,382.3 2028 Senior Notes 395.9 395.4 2029 Senior Notes 936.1 934.5 Total long-term debt obligations $ 2,814.6 $ 2,712.2 Total debt obligations $ 2,822.1 $ 3,025.2
Schedule of Line of Credit Facilities	Interest expense, weighted average interest rates, and the interest rate at the end of period under the 2021 and 2018 Credit Agreements were as follows: Three Months Ended Nine Months Ended June 25, 2022 June 26, 2021 June 25, 2022 June 26, 2021 Interest expense $ 7.8 $ 5.1 $ 18.8 $ 17.0 Weighted average interest rate 1.67 % 1.10 % 1.30 % 1.15 % Interest rate at end of period 2.63 % 1.09 % 2.63 % 1.09 %
Schedule Of Interest Expense Under Convertible Notes	Interest expense for the 2029 Senior Notes, 2028 Senior Notes and 2025 Senior Notes was as follows: Three Months Ended Nine Months Ended Interest Rate June 25, 2022 June 26, 2021 June 25, 2022 June 26, 2021 2025 Senior Notes 4.375 % $ — $ — $ — $ 2.3 2028 Senior Notes 4.625 % 4.8 4.8 14.4 14.4 2029 Senior Notes 3.250 % 8.2 8.2 24.6 24.5 Total $ 13.0 $ 13.0 $ 39.0 $ 41.2

Derivatives (Tables)

Derivatives (Tables)	9 Months Ended
	Jun. 25, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments, Gain (Loss)	Three Months Ended Nine Months Ended June 25, 2022 June 26, 2021 June 25, 2022 June 26, 2021 Amount of realized gain (loss) recognized in income Forward foreign currency contracts $ 19.6 $ (7.0) $ 42.4 $ (6.5) Foreign currency option contracts — (1.4) — (4.4) $ 19.6 $ (8.4) $ 42.4 $ (10.9) Amount of unrealized gain (loss) recognized in income Forward foreign currency contracts $ 2.5 $ 1.5 $ 9.2 $ (2.0) Foreign currency option contracts — 0.4 — (5.5) $ 2.5 $ 1.9 $ 9.2 $ (7.5) Amount of gain (loss) recognized in income Total $ 22.1 $ (6.5) $ 51.6 $ (18.4)
Schedule of Derivative Assets at Fair Value	The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the balance sheet as of June 25, 2022: Balance Sheet Location June 25, 2022 September 25, 2021 Assets: Derivative instruments designated as a cash flow hedge: Interest rate swap contract Prepaid expenses and other current assets $ 19.0 $ — Interest rate swap contract Other assets 9.6 — $ 28.6 $ — Derivatives not designated as hedging instruments: Forward foreign currency contracts Prepaid expenses and other current assets $ 10.3 $ 1.7 $ 10.3 $ 1.7 Liabilities: Derivative instruments designated as a cash flow hedge: Interest rate swap contract Accrued expenses $ — $ 11.1 Interest rate swap contract Other long-term liabilities — 7.6 Total $ — $ 18.7 Derivatives not designated as hedging instruments: Forward foreign currency contracts Accrued expenses $ — $ 0.6
Schedule of Unrealized Loss Recognized in AOCI	The following table presents the unrealized gain (loss) recognized in AOCI related to the interest rate caps and interest rate swap for the following reporting periods: Three Months Ended Nine Months Ended June 25, 2022 June 26, 2021 June 25, 2022 June 26, 2021 Amount of gain (loss) recognized in other comprehensive income, net of taxes: Interest rate swap $ 8.4 $ 3.0 $ 35.7 $ 8.2 Interest rate cap agreements — — — (0.2) Total $ 8.4 $ 3.0 $ 35.7 $ 8.0

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	9 Months Ended
	Jun. 25, 2022
Earnings Per Share [Abstract]
Reconciliation of Basic and Diluted Share Amounts	A reconciliation of basic and diluted share amounts is as follows: Three Months Ended Nine Months Ended June 25, June 26, June 25, June 26, Basic weighted average common shares outstanding 250,756 256,230 251,943 257,769 Weighted average common stock equivalents from assumed exercise of stock options and issuance of restricted stock units 2,337 2,351 2,330 2,602 Diluted weighted average common shares outstanding 253,093 258,581 254,273 260,371 Weighted-average anti-dilutive shares related to: Outstanding stock options and restricted stock units 1,066 653 1,021 515

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Jun. 25, 2022
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation Expense in Consolidated Statements of Operations	The following presents stock-based compensation expense in the Company’s Consolidated Statements of Income: Three Months Ended Nine Months Ended June 25, June 26, June 25, June 26, Cost of revenues $ 2.2 $ 1.9 $ 7.1 $ 6.4 Research and development 1.8 1.4 7.3 6.2 Selling and marketing 2.6 2.3 8.0 7.7 General and administrative 8.7 8.9 29.4 29.8 Restructuring — 0.9 — 0.9 $ 15.3 $ 15.4 $ 51.8 $ 51.0
Weighted-Average Assumptions Utilized to Value Stock Options	The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table: Three Months Ended Nine Months Ended June 25, June 26, June 25, June 26, Risk-free interest rate 1.1 % 0.4 % 1.1 % 0.4 % Expected volatility 34.2 % 35.0 % 34.2 % 35.0 % Expected life (in years) 4.8 4.8 4.8 4.8 Dividend yield — — — — Weighted average fair value of options granted $ 21.48 $ 19.17 $ 21.03 $ 20.07

Other Balance Sheet Informati_2

Other Balance Sheet Information (Tables)	9 Months Ended
	Jun. 25, 2022
Balance Sheet Related Disclosures [Abstract]
Other Balance Sheet Information of Inventories	June 25, September 25, Inventories Raw materials $ 228.9 $ 163.3 Work-in-process 59.5 53.0 Finished goods 292.8 284.9 $ 581.2 $ 501.2
Other Balance Sheet Information of Property, Plant and Equipment	Property, plant and equipment Equipment $ 414.7 $ 467.1 Equipment under customer usage agreements 492.5 484.6 Building and improvements 196.2 191.2 Leasehold improvements 51.0 49.7 Land 41.1 41.3 Furniture and fixtures 17.5 16.8 Finance lease right of use asset 8.2 9.9 $ 1,221.2 $ 1,260.6 Less – accumulated depreciation and amortization (731.1) (695.9) $ 490.1 $ 564.7

Business Segments and Geograp_2

Business Segments and Geographic Information (Tables)	9 Months Ended
	Jun. 25, 2022
Segment Reporting [Abstract]
Segment Information	egment information is as follows: Three Months Ended Nine Months Ended June 25, June 26, June 25, June 26, Total revenues: Diagnostics $ 560.1 $ 665.5 $ 2,497.6 $ 2,858.2 Breast Health 282.8 349.0 952.7 1,018.0 GYN Surgical 138.1 127.9 389.6 366.2 Skeletal Health 21.7 25.9 69.7 73.3 $ 1,002.7 $ 1,168.3 $ 3,909.6 $ 4,315.7 Income (loss) from operations: Diagnostics $ 175.0 $ 260.1 $ 1,247.4 $ 1,745.1 Breast Health 32.0 81.0 163.1 235.1 GYN Surgical 60.1 18.2 92.4 60.5 Skeletal Health (3.2) (0.7) (3.6) 0.1 $ 263.9 $ 358.6 $ 1,499.3 $ 2,040.8 Depreciation and amortization: Diagnostics $ 67.8 $ 63.9 $ 205.4 $ 179.4 Breast Health 16.9 13.6 45.5 39.7 GYN Surgical 24.7 23.2 72.1 69.5 Skeletal Health 0.2 0.2 0.5 0.5 $ 109.6 $ 100.9 $ 323.5 $ 289.1 Capital expenditures: Diagnostics $ 19.8 $ 35.7 $ 77.3 $ 113.2 Breast Health 2.2 4.5 9.2 10.1 GYN Surgical 2.8 3.0 6.9 9.5 Skeletal Health 0.1 0.2 0.3 0.2 Corporate 0.8 — 1.9 1.0 $ 25.7 $ 43.4 $ 95.6 $ 134.0 June 25, September 25, Identifiable assets: Diagnostics $ 3,029.8 $ 3,348.8 Breast Health 1,244.0 1,233.9 GYN Surgical 1,488.2 1,369.7 Skeletal Health 25.8 31.9 Corporate 3,569.6 2,935.6 $ 9,357.4 $ 8,919.9
Revenues by Geography	Revenues by geography as a percentage of total revenues were as follows: Three Months Ended Nine Months Ended June 25, June 26, June 25, June 26, United States 73.3 % 64.2 % 70.1 % 68.4 % Europe 16.4 % 24.7 % 19.2 % 22.3 % Asia-Pacific 7.1 % 7.7 % 7.7 % 6.2 % Rest of World 3.2 % 3.4 % 3.0 % 3.1 % 100.0 % 100.0 % 100.0 % 100.0 %

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	9 Months Ended
	Jun. 25, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consisted of the following: Description As of June 25, 2022 As of September 25, 2021 Gross Accumulated Gross Accumulated Acquired intangible assets: Developed technology $ 4,605.7 $ 3,389.8 $ 4,597.7 $ 3,184.2 In-process research and development 64.5 — 71.6 — Customer relationships 607.9 530.9 591.7 510.1 Trade names 267.1 200.0 268.1 191.8 Non-competition agreements 1.4 1.4 1.5 1.5 Business licenses 2.4 2.4 2.5 2.5 Total acquired intangible assets $ 5,549.0 $ 4,124.5 $ 5,533.1 $ 3,890.1 Internal-use software 23.6 17.5 23.5 17.2 Capitalized software embedded in products 26.1 20.2 25.5 15.6 Total intangible assets $ 5,598.7 $ 4,162.2 $ 5,582.1 $ 3,922.9
Schedule of Estimated Amortization Expense	The estimated remaining amortization expense of the Company's acquired intangible assets as of June 25, 2022 for each of the five succeeding fiscal years was as follows: Remainder of Fiscal 2022 $ 86.2 Fiscal 2023 $ 236.6 Fiscal 2024 $ 227.6 Fiscal 2025 $ 213.1 Fiscal 2026 $ 178.8

Product Warranties (Tables)

Product Warranties (Tables)	9 Months Ended
	Jun. 25, 2022
Guarantees [Abstract]
Product Warranty Activity	Product warranty activity was as follows: Balance at Provisions Acquired Settlements/ Balance at Nine Months Ended: June 25, 2022 $ 8.8 $ 5.1 $ — $ (5.3) $ 8.6 June 26, 2021 $ 9.9 $ 6.1 $ 0.3 $ (6.7) $ 9.6

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
	Jun. 25, 2022
Accumulated Other Comprehensive Income [Abstract]
Changes in Accumulated Other Comprehensive Income	The following tables summarize the changes in accumulated balances of other comprehensive loss for the periods presented: Three Months Ended June 25, 2022 Nine Months Ended June 25, 2022 Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Beginning Balance $ (115.4) $ (1.3) $ 12.6 $ (104.1) $ (43.1) $ (1.3) $ (14.7) $ (59.1) Other comprehensive income (loss) before reclassifications (52.0) — 8.4 (43.6) (124.3) — 35.7 (88.6) Ending Balance $ (167.4) $ (1.3) $ 21.0 $ (147.7) $ (167.4) $ (1.3) $ 21.0 $ (147.7) Three Months Ended June 26, 2021 Nine Months Ended June 26, 2021 Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Foreign Currency Translation Pension Plans Hedged Interest Rate Caps Hedged Interest Rate Swaps Total Beginning Balance $ (14.5) $ (1.8) $ (19.5) $ (35.8) $ (22.9) $ (1.8) $ (0.9) $ (24.1) $ (49.7) Other comprehensive income (loss) before reclassifications (9.4) — 3.0 (6.4) (1.0) — 0.4 7.6 7.0 Amounts reclassified to statement of income — — — — — — 0.5 — 0.5 Ending Balance $ (23.9) $ (1.8) $ (16.5) $ (42.2) $ (23.9) $ (1.8) $ — $ (16.5) $ (42.2)

Revenue - Business Revenue (Det

Revenue - Business Revenue (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021	Jun. 25, 2022	Jun. 26, 2021
Disaggregation of Revenue [Line Items]
Revenues	$ 1,002.7	$ 1,168.3	$ 3,909.6	$ 4,315.7
Contract with Customer, Liability, Revenue Recognized	21.4	20.1	108.7	100.9
United States
Disaggregation of Revenue [Line Items]
Revenues	734.6	749.9	2,739.4	2,951.7
International
Disaggregation of Revenue [Line Items]
Revenues	268.1	418.4	1,170.2	1,364
Diagnostics
Disaggregation of Revenue [Line Items]
Revenues	560.1	665.5	2,497.6	2,858.2
Diagnostics | United States
Disaggregation of Revenue [Line Items]
Revenues	387.4	357.2	1,647.8	1,825.8
Diagnostics | International
Disaggregation of Revenue [Line Items]
Revenues	172.7	308.3	849.8	1,032.4
Diagnostics | Cytology & Perinatal
Disaggregation of Revenue [Line Items]
Revenues	115.9	115.9	362	357.9
Diagnostics | Cytology & Perinatal | United States
Disaggregation of Revenue [Line Items]
Revenues	74.3	73.9	227.4	230.8
Diagnostics | Cytology & Perinatal | International
Disaggregation of Revenue [Line Items]
Revenues	41.6	42	134.6	127.1
Diagnostics | Molecular Diagnostics
Disaggregation of Revenue [Line Items]
Revenues	435.3	536.4	2,111.1	2,467
Diagnostics | Molecular Diagnostics | United States
Disaggregation of Revenue [Line Items]
Revenues	304.2	270.1	1,395.9	1,561.7
Diagnostics | Molecular Diagnostics | International
Disaggregation of Revenue [Line Items]
Revenues	131.1	266.3	715.2	905.3
Diagnostics | Blood Screening
Disaggregation of Revenue [Line Items]
Revenues	8.9	13.2	24.5	33.3
Diagnostics | Blood Screening | United States
Disaggregation of Revenue [Line Items]
Revenues	8.9	13.2	24.5	33.3
Diagnostics | Blood Screening | International
Disaggregation of Revenue [Line Items]
Revenues	0	0	0	0
Breast Health
Disaggregation of Revenue [Line Items]
Revenues	282.8	349	952.7	1,018
Breast Health | United States
Disaggregation of Revenue [Line Items]
Revenues	222.3	273.2	732.9	784.4
Breast Health | International
Disaggregation of Revenue [Line Items]
Revenues	60.5	75.8	219.8	233.6
Breast Health | Breast Imaging
Disaggregation of Revenue [Line Items]
Revenues	212.2	280.3	739.5	817.8
Breast Health | Breast Imaging | United States
Disaggregation of Revenue [Line Items]
Revenues	165.5	218.4	561.8	619.5
Breast Health | Breast Imaging | International
Disaggregation of Revenue [Line Items]
Revenues	46.7	61.9	177.7	198.3
Breast Health | Interventional Breast Solutions
Disaggregation of Revenue [Line Items]
Revenues	70.6	68.7	213.2	200.2
Breast Health | Interventional Breast Solutions | United States
Disaggregation of Revenue [Line Items]
Revenues	56.8	54.8	171.1	164.9
Breast Health | Interventional Breast Solutions | International
Disaggregation of Revenue [Line Items]
Revenues	13.8	13.9	42.1	35.3
GYN Surgical
Disaggregation of Revenue [Line Items]
Revenues	138.1	127.9	389.6	366.2
GYN Surgical | United States
Disaggregation of Revenue [Line Items]
Revenues	112.2	103.9	315.4	296.8
GYN Surgical | International
Disaggregation of Revenue [Line Items]
Revenues	25.9	24	74.2	69.4
Skeletal Health
Disaggregation of Revenue [Line Items]
Revenues	21.7	25.9	69.7	73.3
Skeletal Health | United States
Disaggregation of Revenue [Line Items]
Revenues	12.7	15.6	43.3	44.7
Skeletal Health | International
Disaggregation of Revenue [Line Items]
Revenues	$ 9	$ 10.3	$ 26.4	$ 28.6

Revenue - Geographical Revenue

Revenue - Geographical Revenue (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021	Jun. 25, 2022	Jun. 26, 2021
Disaggregation of Revenue [Line Items]
Revenues	$ 1,002.7	$ 1,168.3	$ 3,909.6	$ 4,315.7
United States
Disaggregation of Revenue [Line Items]
Revenues	734.6	749.9	2,739.4	2,951.7
Europe
Disaggregation of Revenue [Line Items]
Revenues	164.5	289	750.8	963.9
Asia-Pacific
Disaggregation of Revenue [Line Items]
Revenues	71.7	89.6	301.1	268.1
Rest of World
Disaggregation of Revenue [Line Items]
Revenues	$ 31.9	$ 39.8	$ 118.3	$ 132

Revenue - Revenue by Type (Deta

Revenue - Revenue by Type (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021	Jun. 25, 2022	Jun. 26, 2021
Disaggregation of Revenue [Line Items]
Revenues	$ 1,002.7	$ 1,168.3	$ 3,909.6	$ 4,315.7
Contract with Customer, Liability, Revenue Recognized	21.4	20.1	108.7	100.9
Disposables
Disaggregation of Revenue [Line Items]
Revenues	713	797.7	2,930.5	3,239.2
Capital equipment, components and software
Disaggregation of Revenue [Line Items]
Revenues	124.1	197.5	478.2	590.2
Service
Disaggregation of Revenue [Line Items]
Revenues	160.8	158.4	486.2	437.2
Other
Disaggregation of Revenue [Line Items]
Revenues	$ 4.8	$ 14.7	$ 14.7	$ 49.1

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021	Jun. 25, 2022	Jun. 26, 2021
Revenue from Contract with Customer [Abstract]
Revenue, Remaining Performance Obligation, Amount	$ 844.4		$ 844.4
Contract with Customer, Liability, Revenue Recognized	$ 21.4	$ 20.1	$ 108.7	$ 100.9

Revenue - Remaining Performance

Revenue - Remaining Performance Obligation (Details)	Jun. 25, 2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-03-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	12%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-03-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	39%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-03-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	26%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-03-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	15%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-03-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	8%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year

Leases - Additional Lease Infor

Leases - Additional Lease Information (Details)	3 Months Ended
	Jun. 25, 2022
Leases [Abstract]
Lease revenue as a percentage of total (percentage)	0.05

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) $ in Millions	Jun. 25, 2022 USD ($)
Assets:
Assets measured at fair value on a recurring basis	$ 38.9
Liabilities:
Total	23.4
Contingent consideration
Liabilities:
Contingent consideration	23.4
Interest rate swap
Assets:
Assets measured at fair value on a recurring basis	28.6
Forward foreign currency contracts
Assets:
Assets measured at fair value on a recurring basis	10.3
Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Assets measured at fair value on a recurring basis	0
Liabilities:
Total	0
Quoted Prices in Active Market for Identical Assets (Level 1) | Contingent consideration
Liabilities:
Contingent consideration	0
Quoted Prices in Active Market for Identical Assets (Level 1) | Interest rate swap
Assets:
Assets measured at fair value on a recurring basis	0
Quoted Prices in Active Market for Identical Assets (Level 1) | Forward foreign currency contracts
Assets:
Assets measured at fair value on a recurring basis	0
Significant Other Observable Inputs (Level 2)
Assets:
Assets measured at fair value on a recurring basis	38.9
Liabilities:
Total	0
Significant Other Observable Inputs (Level 2) | Contingent consideration
Liabilities:
Contingent consideration	0
Significant Other Observable Inputs (Level 2) | Interest rate swap
Assets:
Assets measured at fair value on a recurring basis	28.6
Significant Other Observable Inputs (Level 2) | Forward foreign currency contracts
Assets:
Assets measured at fair value on a recurring basis	10.3
Significant Unobservable Inputs (Level 3)
Assets:
Assets measured at fair value on a recurring basis	0
Liabilities:
Total	23.4
Significant Unobservable Inputs (Level 3) | Contingent consideration
Liabilities:
Contingent consideration	23.4
Significant Unobservable Inputs (Level 3) | Interest rate swap
Assets:
Assets measured at fair value on a recurring basis	0
Significant Unobservable Inputs (Level 3) | Forward foreign currency contracts
Assets:
Assets measured at fair value on a recurring basis	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 25, 2022	Mar. 26, 2022	Jun. 25, 2022	Jun. 26, 2021
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Intangible asset impairment charge	$ 9.2		$ 9.2	$ 0
Equity Method Investments
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Loss on Sale of Investments		$ 4.3
Credit Agreement
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Borrowed principal	1,500		1,500
2028 Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Fair value of debt instrument	$ 379.9		$ 379.9
2028 Senior Notes | Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Stated interest rate	4.625%		4.625%
2029 Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Fair value of debt instrument	$ 817.6		$ 817.6
2029 Senior Notes | Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Stated interest rate	3.25%		3.25%

Fair Value Measurements - Roll

Fair Value Measurements - Roll Forward (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021	Jun. 25, 2022	Jun. 26, 2021
Fair Value Disclosures [Abstract]
Beginning balance	$ 58.8	$ 71.7	$ 75.1	$ 81.8
Contingent consideration recorded at acquisition	0	0	0	0
Fair value adjustments	(35.4)	0	(39.5)	(10.1)
Payments	0	0	(12.2)	0
Ending balance	$ 23.4	$ 71.7	$ 23.4	$ 71.7

Business Combination - Narrativ

Business Combination - Narrative (Details) - USD ($) $ in Millions

3 Months Ended

9 Months Ended

Nov. 29, 2021

Jun. 17, 2021

Mar. 01, 2021

Feb. 22, 2021

Jan. 04, 2021

Sep. 28, 2020

Aug. 23, 2020

Jun. 25, 2022

Dec. 25, 2021

Mar. 27, 2021

Jun. 25, 2022

Jun. 26, 2021

Sep. 25, 2021

Business Acquisition [Line Items]

Goodwill

$ 3,285.9

$ 3,285.9

$ 3,281.6

Change in contingent consideration

(39.5)

$ (10.1)

Bolder Surgical

Business Acquisition [Line Items]

Consideration transferred

$ 160.1

Intangible assets, fair value (percentage)

16%

Developed technology

$ 73.6

Customer relationships

21.7

Trade names

1.4

Goodwill

$ 70.9

Bolder Surgical | Developed Technology

Business Acquisition [Line Items]

Intangible assets useful life

10 years

Bolder Surgical | Customer Relationships

Business Acquisition [Line Items]

Intangible assets useful life

10 years

Bolder Surgical | Trade Names

Business Acquisition [Line Items]

Intangible assets useful life

10 years

Mobidiag Oy

Business Acquisition [Line Items]

Consideration transferred

$ 729.6

Developed technology

285

Customer relationships

20.9

Trade names

20

Goodwill

$ 427.7

Mobidiag Oy | Minimum

Business Acquisition [Line Items]

Intangible assets, fair value (percentage)

15%

Mobidiag Oy | Maximum

Business Acquisition [Line Items]

Intangible assets, fair value (percentage)

19%

Mobidiag Oy | Developed Technology

Business Acquisition [Line Items]

Intangible assets useful life

11 years 8 months 12 days

Mobidiag Oy | Customer Relationships

Business Acquisition [Line Items]

Intangible assets useful life

9 years 1 month 6 days

Mobidiag Oy | Trade Names

Business Acquisition [Line Items]

Intangible assets useful life

11 years 7 months 6 days

Biotheranostics

Business Acquisition [Line Items]

Consideration transferred

$ 231.3

Intangible assets, fair value (percentage)

18%

Intangible assets useful life

10 years

Developed technology

$ 160.3

Trade names

2.1

Goodwill

$ 80.9

Diagenode

Business Acquisition [Line Items]

Consideration transferred

$ 155.1

Intangible assets useful life

10 years

Developed technology

$ 69.8

Customer relationships

9.2

Goodwill

$ 83.5

Diagenode | Developed Technology

Business Acquisition [Line Items]

Intangible assets, fair value (percentage)

14.50%

Diagenode | Customer Relationships

Business Acquisition [Line Items]

Intangible assets, fair value (percentage)

13.50%

Somatex Medical Technologies

Business Acquisition [Line Items]

Consideration transferred

$ 62.9

Developed technology

38

Customer relationships

1.2

Trade names

0.9

Goodwill

32.4

Net acquired tangible assets and liabilities

$ 9.6

Somatex Medical Technologies | Developed Technology

Business Acquisition [Line Items]

Intangible assets useful life

8 years

NXC Imaging

Business Acquisition [Line Items]

Consideration transferred

$ 5.6

NXC Imaging | Customer Relationships

Business Acquisition [Line Items]

Intangible assets useful life

5 years

Acessa Health

Business Acquisition [Line Items]

Contingent consideration

$ 81.8

23.4

23.4

$ 75.1

Annual incremental revenue growth period

3 years

Change in contingent consideration

35.4

$ 4.1

$ 39.5

$ 10.1

Contingent consideration payment

$ 12.2

Business Combinations Business

Business Combinations Business Combinations - Purchase Price Allocation (Details) - USD ($) $ in Millions	Jun. 25, 2022	Nov. 29, 2021	Sep. 25, 2021	Jun. 17, 2021	Mar. 01, 2021	Feb. 22, 2021
Business Acquisition [Line Items]
Goodwill	$ 3,285.9		$ 3,281.6
Bolder Surgical
Business Acquisition [Line Items]
Cash		$ 1.9
Accounts receivable		1.3
Inventory		3.3
Other assets		3
Accounts payable and accrued expenses		(3.2)
Developed technology		73.6
Customer relationships		21.7
Trade names		1.4
Deferred income taxes, net		(13.8)
Goodwill		70.9
Purchase Price		$ 160.1
Mobidiag Oy
Business Acquisition [Line Items]
Cash				$ 7
Accounts receivable				4.2
Inventory				12.1
Other assets				29.6
Accounts payable and accrued expenses				(16.5)
Other liabilities				(12.2)
Developed technology				285
In-process research and development				74
Customer relationships				20.9
Trade names				20
Long-term debt				(66.1)
Deferred income taxes, net				(56.1)
Goodwill				427.7
Purchase Price				$ 729.6
Biotheranostics
Business Acquisition [Line Items]
Cash						$ 9.6
Accounts receivable						6.6
Other assets						6.5
Accounts payable and accrued expenses						(8.2)
Other liabilities						(8.1)
Developed technology						160.3
Trade names						2.1
Deferred income taxes, net						(18.4)
Goodwill						80.9
Purchase Price						$ 231.3
Diagenode
Business Acquisition [Line Items]
Cash					$ 5.6
Accounts receivable					9.3
Inventory					9
Other assets					13.9
Accounts payable and accrued expenses					(16.7)
Other liabilities					(9.2)
Developed technology					69.8
Customer relationships					9.2
Deferred income taxes, net					(19.3)
Goodwill					83.5
Purchase Price					$ 155.1

Trade Receivables and Allowan_3

Trade Receivables and Allowance for Credit Losses (Details) - USD ($) $ in Millions	9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance at Beginning of Period	$ 40.5	$ 31.6
Credit Loss	4.4	11.6
Write- offs and Payments	(3.9)	(3.4)
Balance at End of Period	$ 41	$ 39.8

Restructuring (Details)

Restructuring (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021	Jun. 25, 2022	Jun. 26, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Restructuring and divestiture charges	$ 0.8	$ 3.6	$ 0.8	$ 6.6
Danbury closure
Restructuring Costs [Abstract]
Restructuring and Related Cost, Expected Cost	7		7
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Restructuring and Related Cost, Expected Cost	$ 7		$ 7

Borrowings and Credit Arrange_3

Borrowings and Credit Arrangements - Company's Borrowings (Detail) - USD ($) $ in Millions	Jun. 25, 2022	Sep. 25, 2021
Debt Instrument [Line Items]
Current portion of long-term debt	$ 7.5	$ 313
Total long-term debt obligations	2,814.6	2,712.2
Total debt obligations	2,822.1	3,025.2
Term Loan
Debt Instrument [Line Items]
Current portion of long-term debt	7.5	0
Long term debt obligations. excluding convertible notes	1,482.6	1,382.3
Accounts Receivable Securitization
Debt Instrument [Line Items]
Current portion of long-term debt	0	248.5
Other Debt Obligations
Debt Instrument [Line Items]
Current portion of long-term debt	0	64.5
2028 Senior Notes
Debt Instrument [Line Items]
Long term debt obligations. excluding convertible notes	395.9	395.4
2029 Senior Notes
Debt Instrument [Line Items]
Long term debt obligations. excluding convertible notes	$ 936.1	$ 934.5

Borrowings and Credit Arrange_4

Borrowings and Credit Arrangements - Additional Information (Detail) $ in Thousands			3 Months Ended				9 Months Ended
	Sep. 27, 2021 USD ($)	Oct. 15, 2020 USD ($)	Jun. 25, 2022 USD ($)	Dec. 25, 2021 USD ($)	Jun. 26, 2021 USD ($)	Mar. 27, 2021 USD ($)	Jun. 25, 2022 USD ($)	Jun. 26, 2021 USD ($)	Sep. 25, 2021 USD ($)	Jun. 17, 2021	Sep. 28, 2020 USD ($)
Debt Instrument [Line Items]
Long-term debt			$ 2,822,100				$ 2,822,100		$ 3,025,200
Debt extinguishment losses			0		$ 0	$ 21,600	700	$ 21,600
Long-term Debt, Current Maturities			$ 7,500				$ 7,500		313,000
Repayments of Other Debt				$ 63,700
Minimum | Mobidiag Oy
Debt Instrument [Line Items]
Stated interest rate										6%
Maximum | Mobidiag Oy
Debt Instrument [Line Items]
Stated interest rate										7%
2021 Credit Agreement
Debt Instrument [Line Items]
Proceeds from revolving credit line	$ 1,500,000
Revolver | 2021 Revolver
Debt Instrument [Line Items]
Revolving credit facility borrowings	2,000,000
Senior Notes | 2025 Senior Notes
Debt Instrument [Line Items]
Stated interest rate			4.375%				4.375%
Senior notes, face amount		$ 950,000	$ 950,000				$ 950,000
Interest Expense, Debt				5,800
Debt Issuance Costs, Net				7,900
Debt Instrument, Unamortized Discount				6,400
Premium payment		20,800
Extinguishment of Debt, Amount		$ 970,800
Senior Notes | 2028 Senior Notes
Debt Instrument [Line Items]
Stated interest rate			4.625%				4.625%
Senior Notes | 2029 Senior Notes
Debt Instrument [Line Items]
Stated interest rate			3.25%				3.25%
Senior notes			$ 950,000				$ 950,000				$ 950,000
Debt Instrument, Offering Price, Percent Of Face Value											1
2028 Senior Notes
Debt Instrument [Line Items]
Senior notes, face amount			400,000				400,000
Term Loan
Debt Instrument [Line Items]
Long-term Debt, Current Maturities			7,500				7,500		0
Term Loan | 2021 Credit Agreement
Debt Instrument [Line Items]
Debt extinguishment losses				$ 700
Debt Issuance Costs, Net			7,000				7,000
Accounts Receivable Securitization
Debt Instrument [Line Items]
Long-term Debt, Current Maturities			$ 0				$ 0		$ 248,500
Secured Term Loan | 2021 Term Loan
Debt Instrument [Line Items]
Stated interest rate			2.63%				2.63%
Senior notes, face amount	1,500,000
Secured Term Loan | 2021 Term Loan | Eurocurrency Rate
Debt Instrument [Line Items]
Debt Instrument, Commitment Fee, Percentage							0.15%
Debt Instrument, Periodic Payment, Principal Per Quarter	1,335,000
Secured Term Loan | 2021 Term Loan | Minimum | Eurocurrency Rate
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal Per Quarter	3,750
Secured Term Loan | 2021 Term Loan | Maximum | Eurocurrency Rate
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal Per Quarter	$ 18,750
Asset Securitization
Debt Instrument [Line Items]
Repayments of Other Debt			$ 248,500

Borrowings and Credit Arrange_5

Borrowings and Credit Arrangements - Interest Expense Credit Agreement (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021	Jun. 25, 2022	Jun. 26, 2021
Line of Credit Facility [Line Items]
Interest expense	$ 13	$ 13	$ 39	$ 41.2
Credit Agreement
Line of Credit Facility [Line Items]
Interest expense	$ 7.8	$ 5.1	$ 18.8	$ 17
Weighted average interest rate	1.67%	1.10%	1.30%	1.15%
Interest rate at end of period	2.63%	1.09%	2.63%	1.09%

Borrowings and Credit Arrange_6

Borrowings and Credit Arrangements - Interest Expense Senior Notes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021	Jun. 25, 2022	Jun. 26, 2021
Line of Credit Facility [Line Items]
Interest expense	$ 13	$ 13	$ 39	$ 41.2
Senior Notes | 2028 Senior Notes
Line of Credit Facility [Line Items]
Stated interest rate	4.625%		4.625%
Interest expense	$ 4.8	4.8	$ 14.4	14.4
Senior Notes | 2025 Senior Notes
Line of Credit Facility [Line Items]
Stated interest rate	4.375%		4.375%
Interest expense	$ 0	0	$ 0	2.3
Senior Notes | 2029 Senior Notes
Line of Credit Facility [Line Items]
Stated interest rate	3.25%		3.25%
Interest expense	$ 8.2	$ 8.2	$ 24.6	$ 24.5

Derivatives - Additional Inform

Derivatives - Additional Information (Details) - USD ($) $ in Millions	Jun. 25, 2022	Sep. 26, 2020
Derivative [Line Items]
Notational Amount	$ 330.2
Interest rate swap
Derivative [Line Items]
Derivative notional amount		$ 1,000
Variable interest rate		1.23%
Interest rate swap at fair value	$ 28.6

Derivatives - Schedule Of Chang

Derivatives - Schedule Of Change in Fair Value Of Derivative Contracts (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021	Jun. 25, 2022	Jun. 26, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Total	$ 22.1	$ (6.5)	$ 51.6	$ (18.4)
Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Amount of realized gain (loss) recognized in income	19.6	(8.4)	42.4	(10.9)
Amount of unrealized gain (loss) recognized in income	2.5	1.9	9.2	(7.5)
Forward foreign currency contracts | Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Amount of realized gain (loss) recognized in income	19.6	(7)	42.4	(6.5)
Amount of unrealized gain (loss) recognized in income	2.5	1.5	9.2	(2)
Foreign currency option contracts | Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Amount of realized gain (loss) recognized in income	0	(1.4)	0	(4.4)
Amount of unrealized gain (loss) recognized in income	$ 0	$ 0.4	$ 0	$ (5.5)

Derivatives - Fair Value of Der

Derivatives - Fair Value of Derivative Financial Instruments (Details) - USD ($) $ in Millions	Jun. 25, 2022	Sep. 25, 2021
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative liability	$ 0	$ 18.7
Interest rate swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swap at fair value	28.6
Derivatives not designated as hedging instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative asset	10.3	1.7
Derivatives not designated as hedging instruments | Forward foreign currency contracts | Prepaid expenses and other current assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swap at fair value	10.3	1.7
Derivatives not designated as hedging instruments | Forward foreign currency contracts | Accrued expenses
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swap at fair value	0	0.6
Derivatives not designated as hedging instruments | Interest rate swap | Accrued expenses
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swap at fair value	0	11.1
Derivatives not designated as hedging instruments | Interest rate swap | Other long-term liabilities
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swap at fair value	0	7.6
Derivative instruments designated as a cash flow hedge | Interest rate swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative asset	28.6	0
Derivative instruments designated as a cash flow hedge | Interest rate swap | Other Current Assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative asset	19	0
Derivative instruments designated as a cash flow hedge | Interest rate swap | Other assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative asset	$ 9.6	$ 0

Derivatives - Gain (Loss) on Fa

Derivatives - Gain (Loss) on Fair Value Hedges Recognized in AOCI (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021	Jun. 25, 2022	Jun. 26, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in other comprehensive income, net of taxes:	$ 8.4	$ 3	$ 35.7	$ 8
Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in other comprehensive income, net of taxes:	8.4	3	35.7	8.2
Interest rate caps - derivative
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in other comprehensive income, net of taxes:	$ 0	$ 0	$ 0	$ (0.2)

Commitments and Contingencies (

Commitments and Contingencies (Detail) $ in Millions		3 Months Ended
	Mar. 04, 2016 petition	Jun. 25, 2022 USD ($)	Jul. 27, 2018 USD ($)
Minerva
Loss Contingencies [Line Items]
Assessed damages			$ 4.8
Petitions filed | petition	2
Medical Aesthetics
Loss Contingencies [Line Items]
Legal Accrual		$ 8.5
Payments for Legal Settlements		$ 8.5

Net Income (Loss) Per Share - R

Net Income (Loss) Per Share - Reconciliation of Basic and Diluted Share Amounts (Detail) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021	Jun. 25, 2022	Jun. 26, 2021
Earnings Per Share [Line Items]
Basic weighted average common shares outstanding	250,756	256,230	251,943	257,769
Weighted average common stock equivalents from assumed exercise of stock options and issuance of restricted stock units	2,337	2,351	2,330	2,602
Diluted weighted average common shares outstanding	253,093	258,581	254,273	260,371
Outstanding Stock Options and stock units
Weighted-average anti-dilutive shares related to:
Weighted-average anti-dilutive shares (in shares)	1,066	653	1,021	515

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021	Jun. 25, 2022	Jun. 26, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 15.3	$ 15.4	$ 51.8	$ 51
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2.2	1.9	7.1	6.4
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	1.8	1.4	7.3	6.2
Selling and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2.6	2.3	8	7.7
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	8.7	8.9	29.4	29.8
Restructuring Charges [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 0	$ 0.9	$ 0	$ 0.9

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021
Stock option plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)	0.7	0.6
Weighted-average exercise prices (in dollars per share)	$ 71.12	$ 68.62
Share-based compensation, stock options outstanding (in shares)	4.4
Weighted-average exercise price of options outstanding (in dollars per share)	$ 48.49
Unrecognized compensation expense	$ 18.4
Weighted-average period for recognition of unrecognized stock-based compensation, years	2 years 3 months 18 days
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.6	0.5
Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share)	$ 71.18	$ 68.45
Unrecognized compensation expense	$ 67.4
Weighted-average period for recognition of unrecognized stock-based compensation, years	2 years
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.1	0.1
Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share)	$ 71.16	$ 68.51
Market Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.1	0.1
Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share)	$ 75.43	$ 82.31
Minimum eligible percentage to receive target number of shares of company's common stock	0%
Maximum eligible percentage to receive target number of shares of company's common stock	200%
Performance stock units vesting period	3 years
PSU Free Cash Flow [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.1	0.1
Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share)	$ 71.16	$ 68.51
Minimum eligible percentage to receive target number of shares of company's common stock	0%
Maximum eligible percentage to receive target number of shares of company's common stock	200%
Performance stock units vesting period	3 years
RSU, PSU, MSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)	1.7

Stock-Based Compensation - Weig

Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021	Jun. 25, 2022	Jun. 26, 2021
Share-based Payment Arrangement [Abstract]
Risk-free interest rate	1.10%	0.40%	1.10%	0.40%
Expected volatility	34.20%	35%	34.20%	35%
Expected life (in years)	4 years 9 months 18 days	4 years 9 months 18 days	4 years 9 months 18 days	4 years 9 months 18 days
Dividend yield	$ 0	$ 0	$ 0	$ 0
Weighted average fair value of options granted	$ 21.48	$ 19.17	$ 21.03	$ 20.07

Other Balance Sheet Informati_3

Other Balance Sheet Information - Inventories (Detail) - USD ($) $ in Millions	Jun. 25, 2022	Sep. 25, 2021
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 228.9	$ 163.3
Work-in-process	59.5	53
Finished goods	292.8	284.9
Inventories	$ 581.2	$ 501.2

Other Balance Sheet Informati_4

Other Balance Sheet Information - Property, Plant and Equipment (Detail) - USD ($) $ in Millions	3 Months Ended				9 Months Ended
	Jun. 25, 2022	Dec. 25, 2021	Jun. 26, 2021	Mar. 27, 2021	Jun. 25, 2022	Sep. 25, 2021
Balance Sheet Related Disclosures [Abstract]
Equipment	$ 414.7				$ 414.7	$ 467.1
Equipment under customer usage agreements	492.5				492.5	484.6
Building and improvements	196.2				196.2	191.2
Leasehold improvements	51				51	49.7
Land	41.1				41.1	41.3
Furniture and fixtures	17.5				17.5	16.8
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	8.2				8.2	9.9
Property, plant and equipment, gross	1,221.2				1,221.2	1,260.6
Less – accumulated depreciation and amortization	(731.1)				(731.1)	(695.9)
Property, plant and equipment, net	490.1				490.1	$ 564.7
Grants received from Department of defense			$ 119.3	$ 7.6
Grants Receivable, Current	20.5				20.5
Department of defense funds received	$ 16.2	$ 21.2			$ 75

Business Segments and Geograp_3

Business Segments and Geographic Information - Additional Information (Detail)	3 Months Ended		6 Months Ended	9 Months Ended
	Jun. 25, 2022 USD ($)	Jun. 26, 2021 USD ($)	Mar. 26, 2022 Segment	Jun. 25, 2022 USD ($)	Jun. 26, 2021 USD ($)
Segment Reporting Disclosure [Line Items]
Number of reportable segments | Segment			4
Revenues	$ 1,002,700,000	$ 1,168,300,000		$ 3,909,600,000	$ 4,315,700,000
Intersegment
Segment Reporting Disclosure [Line Items]
Revenues	$ 0	$ 0		$ 0	$ 0

Business Segments and Geograp_4

Business Segments and Geographic Information - Segment Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021	Jun. 25, 2022	Jun. 26, 2021	Sep. 25, 2021
Segment Reporting Information [Line Items]
Total revenues	$ 1,002.7	$ 1,168.3	$ 3,909.6	$ 4,315.7
Income (loss) from operations	263.9	358.6	1,499.3	2,040.8
Depreciation and amortization	109.6	100.9	323.5	289.1
Capital expenditures	25.7	43.4	95.6	134
Identifiable assets	9,357.4		9,357.4		$ 8,919.9
Diagnostics
Segment Reporting Information [Line Items]
Total revenues	560.1	665.5	2,497.6	2,858.2
Income (loss) from operations	175	260.1	1,247.4	1,745.1
Depreciation and amortization	67.8	63.9	205.4	179.4
Capital expenditures	19.8	35.7	77.3	113.2
Identifiable assets	3,029.8		3,029.8		3,348.8
Breast Health
Segment Reporting Information [Line Items]
Total revenues	282.8	349	952.7	1,018
Income (loss) from operations	32	81	163.1	235.1
Depreciation and amortization	16.9	13.6	45.5	39.7
Capital expenditures	2.2	4.5	9.2	10.1
Identifiable assets	1,244		1,244		1,233.9
GYN Surgical
Segment Reporting Information [Line Items]
Total revenues	138.1	127.9	389.6	366.2
Income (loss) from operations	60.1	18.2	92.4	60.5
Depreciation and amortization	24.7	23.2	72.1	69.5
Capital expenditures	2.8	3	6.9	9.5
Identifiable assets	1,488.2		1,488.2		1,369.7
Skeletal Health
Segment Reporting Information [Line Items]
Total revenues	21.7	25.9	69.7	73.3
Income (loss) from operations	(3.2)	(0.7)	(3.6)	0.1
Depreciation and amortization	0.2	0.2	0.5	0.5
Capital expenditures	0.1	0.2	0.3	0.2
Identifiable assets	25.8		25.8		31.9
Corporate
Segment Reporting Information [Line Items]
Capital expenditures	0.8	$ 0	1.9	$ 1
Identifiable assets	$ 3,569.6		$ 3,569.6		$ 2,935.6

Business Segments and Geograp_5

Business Segments and Geographic Information - Revenues by Geography (Detail)	3 Months Ended		9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021	Jun. 25, 2022	Jun. 26, 2021
Schedule Of Geographical Segments [Line Items]
Revenues	100%	100%	100%	100%
United States
Schedule Of Geographical Segments [Line Items]
Revenues	73.30%	64.20%	70.10%	68.40%
Europe
Schedule Of Geographical Segments [Line Items]
Revenues	16.40%	24.70%	19.20%	22.30%
Asia-Pacific
Schedule Of Geographical Segments [Line Items]
Revenues	7.10%	7.70%	7.70%	6.20%
Rest of World
Schedule Of Geographical Segments [Line Items]
Revenues	3.20%	3.40%	3%	3.10%

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Jun. 25, 2022	Dec. 25, 2021	Jun. 26, 2021	Jun. 25, 2022	Jun. 26, 2021
Income Tax Disclosure [Abstract]
Company's effective tax rate	8.10%		20.60%	18.10%	21%
Proceeds from Income Tax Refunds	$ 422.6
Tax Adjustments, Settlements, and Unusual Provisions	$ 5.2	$ 5.4

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Schedule of Intangible Assets (Detail) - USD ($) $ in Millions	Jun. 25, 2022	Sep. 25, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 5,598.7	$ 5,582.1
Accumulated Amortization	4,162.2	3,922.9
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	4,605.7	4,597.7
Accumulated Amortization	3,389.8	3,184.2
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	64.5	71.6
Accumulated Amortization	0	0
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	607.9	591.7
Accumulated Amortization	530.9	510.1
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	267.1	268.1
Accumulated Amortization	200	191.8
Non-competition agreements
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	1.4	1.5
Accumulated Amortization	1.4	1.5
Business licenses
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	2.4	2.5
Accumulated Amortization	2.4	2.5
Total acquired intangible assets
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	5,549	5,533.1
Accumulated Amortization	4,124.5	3,890.1
Internal-use software
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	23.6	23.5
Accumulated Amortization	17.5	17.2
Capitalized software embedded in products
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	26.1	25.5
Accumulated Amortization	$ 20.2	$ 15.6

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Schedule of Estimated Amortization Expense (Detail) $ in Millions	Jun. 25, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of Fiscal 2022	$ 86.2
Fiscal 2023	236.6
Fiscal 2024	227.6
Fiscal 2025	213.1
Fiscal 2026	$ 178.8

Product Warranties - Product Wa

Product Warranties - Product Warranty Activity (Detail) - USD ($) $ in Millions	9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
Balance at Beginning of Period	$ 8.8	$ 9.9
Provisions	5.1	6.1
Standard and Extended Product Warranty Accrual, Additions from Business Acquisition	0	0.3
Settlements/ Adjustments	(5.3)	(6.7)
Balance at End of Period	$ 8.6	$ 9.6

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 25, 2022	Jun. 26, 2021	Jun. 25, 2022	Jun. 26, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance			$ 4,218.6
Other comprehensive income (loss) before reclassifications	$ (43.6)	$ (6.4)	(88.6)	$ 7
Amounts reclassified to statement of income		0		0.5
Ending balance	4,997.9		4,997.9
Total
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(104.1)	(35.8)	(59.1)	(49.7)
Ending balance	(147.7)	(42.2)	(147.7)	(42.2)
Foreign Currency Translation
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(115.4)	(14.5)	(43.1)	(22.9)
Other comprehensive income (loss) before reclassifications	(52)	(9.4)	(124.3)	(1)
Amounts reclassified to statement of income		0		0
Ending balance	(167.4)	(23.9)	(167.4)	(23.9)
Pension Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(1.3)	(1.8)	(1.3)	(1.8)
Other comprehensive income (loss) before reclassifications	0	0	0	0
Amounts reclassified to statement of income		0		0
Ending balance	(1.3)	(1.8)	(1.3)	(1.8)
Interest rate caps - derivative | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance				(0.9)
Other comprehensive income (loss) before reclassifications				0.4
Amounts reclassified to statement of income				0.5
Ending balance		0		0
Interest Rate Swap | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	12.6	(19.5)	(14.7)	(24.1)
Other comprehensive income (loss) before reclassifications	8.4	3	35.7	7.6
Amounts reclassified to statement of income		0		0
Ending balance	$ 21	$ (16.5)	$ 21	$ (16.5)

Share Repurchase Share repurcha

Share Repurchase Share repurchase (Details) - USD ($) shares in Millions, $ in Millions		3 Months Ended	9 Months Ended
	Dec. 09, 2020	Jun. 25, 2022	Jun. 25, 2022
share repurchase plan [Line Items]
Stock Repurchased During Period, Value		$ 0	$ 367
December 11, 2020
share repurchase plan [Line Items]
Stock Repurchase Program, Authorized Amount	$ 1,000
Stock Repurchase Program, Period in Force	5 years
December 11, 2020
share repurchase plan [Line Items]
Stock Repurchased During Period, Shares			5.2
Stock Repurchase Program, Remaining Authorized Repurchase Amount		$ 324.7	$ 324.7